[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Integra LifeSciences Corp. (NeuroSciences)\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":169},{"warningLetters":4,"total":168},[5,31,50,73,93,113,131,149],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},1094,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-01-14T14:20:00Z\">01\u002F14\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-19T05:00:00Z\">12\u002F19\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintegra-lifesciences-corporation-698850-12192024\">Integra LifeSciences Corporation\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jan De Witte\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Integra LifeSciences Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1100 Campus Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Princeton\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08540\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)@integralife.com\"> (b)(4)@integralife.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 698850\u003C\u002Fp>\u003Cp>December 19, 2024\u003C\u002Fp>\u003Cp>Dear Mr. DeWitte:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) conducted the following inspections of your firm’s medical device facilities:\u003C\u002Fp>\u003Cul>\u003Cli>Integra LifeSciences Corporation, located at 11 Cabot Blvd, Mansfield, MA, FEI 3014334038, from March 12, 2024 through June 5, 2024\u003C\u002Fli>\u003Cli>Integra LifeSciences Corporation, located at 105 And 109 Morgan Ln, Plainsboro, NJ, FEI 1121308, from April 9, 2024 through August 22, 2024\u003C\u002Fli>\u003Cli>Integra LifeSciences Corporation, located at 1100 Campus Rd, Princeton, NJ, FEI 3003418325, from March 12, 2034 through August 22, 2024\u003C\u002Fli>\u003C\u002Ful>\u003Cp>During these inspections, FDA investigators and a microbiologist determined that the above firms manufacture a variety of neurological and neurosurgical devices, including but not limited to, cranial perforators, disposable cottonoid patties and strips as well as collagen based medical devices, that are used for wound care, soft tissue repair and reconstruction surgery. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>The above inspections revealed that the above devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received responses from Jeffrey Caldwell, Vice President, Quality Operations dated June 27, 2024, August 27, 2024, and October 25, 2024 concerning our investigator’s and microbiologist’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm’s Mansfield, MA location on June 5, 2024.\u003C\u002Fp>\u003Cp>We received responses from Brenda Romero, Director, Quality Operations, CMC dated September 27, 2024 and December 5, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm’s Plainsboro, NJ location on August 22, 2024.\u003C\u002Fp>\u003Cp>We received responses from Jessica Smith, Corporate Vice President, Chief Regulatory Officer, and interim Chief Quality Officer dated September 13, 2024 and from Lacey Gigante, Sr. Director, CAPA &amp; Compliance November 15, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm’s Princeton, NJ location on August 22, 2024.\u003C\u002Fp>\u003Cp>We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures to control product that does not conform to specified requirements. The procedures shall address the identification, documentation, evaluation, segregation, and disposition of nonconforming product. The evaluation of nonconformance shall include a determination of the need for an investigation and notification of the persons or organizations responsible for the nonconformance. The evaluation and any investigation shall be documented, as required by 21 CFR § 820.90(a).\u003C\u002Fp>\u003Cp>Specifically, during an inspection of your Mansfield, MA location, a review of 4 non-conforming reports from October 2022 through June 2023 (NC-101352, NC-101446, NC-101628, and NC-101642) were opened due to Out of Specification (OOS) endotoxin results on three separate lots of surgical patties and one lot of Duraform. In the above instances, after the laboratory investigation concluded there was no assignable laboratory error or root cause, your firm retested the lots, even though your Pyrogen Testing procedure, MPS-PC340, did not specify that a retest was allowed. Your firm then released the above referenced lots without conducting a complete investigation of the manufacturing processes, as required by your Non-Conformance procedure, GSOP-773 and MPS-PC340.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated a recall of Duraform, lot CT007694 on September 6, 2024 as well as a recall of multiple lots of surgical patties and strips manufactured between 2022 and 2023 on September 20, 2024. However, your firm continues to implement a number of corrective actions at your Mansfield, MA facility that will not be completed until May 2025.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain procedures for acceptance activities. Acceptance activities include inspections, tests, or other verification activities; as required by 21 CFR § 820.80(a).\u003C\u002Fp>\u003Cp>Specifically, your Plainsboro, NJ location utilizes procedure CMC-MB-049 “Determination of Endotoxin in \u003Cstrong>(b)(4)\u003C\u002Fstrong> Product Using the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Methods” to determine the bacterial endotoxin concentration in products manufactured at the Integra LifeSciences Collagen Manufacturing Center (CMC), Buildings \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including \u003Cstrong>(b)(4)\u003C\u002Fstrong>. According to section 9.6.3.3 of this procedure, “\u003Cem>the Coefficient of Variation (CV%) for each pair of standard series samples must be less than \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fem>” for the overall test to be considered valid. However, during our inspection we observed that ten of fifty-two tests conducted in 2023 failed due to the CV% exceeding the \u003Cstrong>(b)(4)\u003C\u002Fstrong> limit. These ten tests were observed to be repeatedly retested until the CV% fell below \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For example, endotoxin test (LAL-24-2012) and its two subsequent retests (LAL-24-0012 Retest, LAL-24-0012 Retest 2) all failed to meet CV% criteria. It was then retested on a different day under a new ID (LAL-24-0013) and finally passed on the fourth attempt (LAL-24-0013 Retest 3). Your firm’s microbiology manager attributed the CV% failures to low endotoxin concentration in the controls. Additionally, your CMC-MB-049 procedure does not specify the circumstances under which a retest could be performed or which result should be utilized if a retest was conducted.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated three CAPAs (CAPA-00133, CAPA-00134, and CAPA-00135) to address the observations. As part of these CAPAs, we acknowledge that your firm has performed a statistical assessment of historical reagent qualification data for CV% in which you determined that the appropriate CV% for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> EU\u002FmL standard concentration would be \u003Cstrong>(b)(4)\u003C\u002Fstrong>% and made updates to affected procedures, including CMC-MB-049. However, verification of the effectiveness of the corrective actions are still ongoing with a target date of June 2025. Please provide the results of your firm’s planned 6-month effectiveness check when it becomes available.\u003C\u002Fp>\u003Cp>3. Failure to establish and maintain procedures for finished device acceptance to ensure that each production run, lot, or batch of finished devices meets acceptance criteria, as required by 21 CFR § 820.80(d).\u003C\u002Fp>\u003Cp>Specifically, your Mansfield, MA location utilizes MPS-PC340, Preparing Products for Pyrogen Testing (Rev: 068, Effective Date: 30Mar2023) to describe the procedures and materials needed to prepare test samples for pyrogenicity and how to investigate results that exceed acceptable criteria. However, review of this procedure determined it lacks the following requirements to ensure devices meet established endotoxins specifications for device sterility prior to release. For example,\u003C\u002Fp>\u003Cp> Adequate instructions for OOS laboratory investigations where the original endotoxins results are determined to be valid because no laboratory error or assignable cause was found.\u003Cbr> Documentation of how many times the device lot or device extract may be re- analyzed or retested during the investigation after an OOS result is reported.\u003Cbr> Lack of details regarding sample selection to ensure samples are representative of the entire lot to account for endotoxins not evenly distributed within the lot.\u003Cbr> No requirement to include documentation of endotoxin test result units (EU\u002Fml or EU\u002Fdevice) on the \u003Cem>Post-Sterile Release\u003C\u002Fem> section of your Device History Records.\u003C\u002Fp>\u003Cp>For example, verification of Pyrogen Lab Results receipt for Lot # 7260687 of Product Code \u003Cstrong>(b)(4)\u003C\u002Fstrong> lists the Lab Result as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” The Endotoxin Action Limit for this product code is \u003Cstrong>(b)(4)\u003C\u002Fstrong> EU\u002FDevice. Your Bacterial Endotoxin Test Final Report (Study Number 1621708-S01), dated June 15, 2023 concluded that the pooled test articles for Lot # 7260687 “exceeded the endotoxin limit of not more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> EU\u002Fdevice.”\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated NC-001411 on June 7, 2024 and CAPA-100183 on June 11, 2024 to address updates needed to the procedural requirements, updates to DHRs so that BET result units are accurately recorded among other actions. However, your firm continues to implement a number of corrective actions that will not be completed until March 2025.\u003C\u002Fp>\u003Cp>4. Failure to establish and maintain procedures for corrective and preventive action, as required by 21 § CFR 820.100(a). For example,\u003C\u002Fp>\u003Cp>During the inspection of the Princeton, NJ corporate headquarters, your Corrective and Preventive Action (CAPA) Process (GSOP-758; Rev 007), specifically, Section 7.1, describes the process of CAPA Escalation. Section 7.1.2.3 of GSOP-758 describes when a decision is made to not initiate a CAPA, including documentation of the justification for not initiating a CAPA on Form GSOP-758A (CAPA Escalation Decision Form). A review of quality data sources over individual Integra sites, including corrective and preventive actions (CAPAs) and quality plans (QPs) taken at numerous Integra firm locations revealed that site specific CAPAs are not evaluated for escalation to corporate wide CAPAs.\u003C\u002Fp>\u003Cp>For example, CAPA 23-008 opened on April 7, 2023 at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing location in \u003Cstrong>(b)(4)\u003C\u002Fstrong> was related to endotoxin testing at that location. Endotoxin testing is performed at other locations, including collagen manufacturing in Plainsboro, NJ and neurological manufacturing in Mansfield, MA. The decision and justification to not escalate endotoxin testing to a corporate wide CAPA was not documented.\u003C\u002Fp>\u003Cp>Additionally, per Section 5.2.1 of the Quality Objectives &amp; Quality Planning document (GSOP-763; Rev. 003) “\u003Cem>quality planning is not used to investigate or correct actual or potential problems or concerns arising from the QMS or its data sources\u003C\u002Fem>.” However, during our inspections, you provided several quality plans that were being utilized for investigating or correcting actual and potential problems with the quality systems. The GSOP-763 procedure used for quality planning does not include pertinent sections required for corrective and preventive actions such as: investigating the cause of nonconformities, identifying the actions needed to correct and prevent recurrence, and verifying or validating the action to ensure it is effective. These sections are found within the CAPA procedure GSOP-758. At the time of our inspections, CAPAs had not been opened to address these issues. Examples of quality plans currently being used to correct problems with the quality system are:\u003C\u002Fp>\u003Cp>• At your Princeton, NJ location\u003Cbr>&nbsp; &nbsp; o QP-2023-12, Quality Plan for Assessing Endotoxin Program Compliance, initiated on March 25, 2024 to assess endotoxin issues across Integra organizations. This quality plan lists a target completion date for site-specific gap assessments as 12\u002F31\u002F2026 and the target due date for developing an action plan to close and\u002For mitigate any identified compliance gaps as 6\u002F30\u002F2027.\u003Cbr>• At your Plainsboro, NJ location\u003Cbr>&nbsp; &nbsp; o QP-2023-02, Quality Plan for the Closure of Overdue SCARs at the Collagen Manufacturing Center, initiated on December 7, 2023 to document the closure of overdue SCARs at the Collagen Manufacturing Center (CMC). Eleven SCARs were identified as overdue in section 2.2 of this document.\u003Cbr>• At your Mansfield, MA location\u003Cbr>&nbsp; &nbsp; o QP-20-001, Quality Plan for CerebroFlo EVD Catheter design history file remediation initiated on April 9, 2020, to address 30 observations found during a third-party review of the CerebroFlo EVD catheter design project.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated several CAPAs at multiple sites, including a corporate-wide CAPA-00143 on September 6, 2024 to address the extension of CAPAs and Quality Plans across multiple Integra locations including planned implementation of a CAPA escalation decision tree and form by December 15, 2024; planned review of all CAPAs initiated at Integra corporate and all manufacturing sites since November 2, 2022; and planned updates to GSOP-758 to require an evaluation of each CAPA to determine whether it may be applicable to multiple manufacturing sites. However, your firm continues to implement corrective actions that will not be completed until November 2025 when verification of effectiveness is targeted to be completed.\u003C\u002Fp>\u003Cp>5. Failure to review and evaluate process changes and deviations and perform revalidation when changes or process deviations occur, as required by 21 CFR § 820.75(c).\u003C\u002Fp>\u003Cp>For example, at your Mansfield, MA location, your firm failed to assess the impact of annual sterilization requalification parameter failures for Ethylene Oxide (EO) cycle #\u003Cstrong>(b)(4)\u003C\u002Fstrong> used to demonstrate a continued sterility assurance level of \u003Cstrong>(b)(4)\u003C\u002Fstrong> EO sterilization is performed by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. EO cycle #\u003Cstrong>(b)(4)\u003C\u002Fstrong> is used sterilization of several devices manufactured at Mansfield, MA including neurological surgical patties. For example,\u003C\u002Fp>\u003Cp>• On December 2, 2020, a deviation occurred with eight temperature sensors recording temperatures below the minimum \u003Cstrong>(b)(4)\u003C\u002Fstrong> degrees Fahrenheit for the product temperature during the EO exposure dwell phase, failing to meet the predetermined validation acceptance criteria of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>&nbsp; &nbsp; o Your firm failed to investigate the cause of the temperature failure and the potential effect on the EO cycle for routine sterilization.\u003C\u002Fp>\u003Cp>• The 2022 requalification of the EO cycle \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Vessel #1 and Vessel # 2, (\u003Cstrong>(b)(4)\u003C\u002Fstrong>-0007898) approved by your firm on November 23, 2022, exceeded your firm’s predetermined acceptance criteria for product load relative humidity (RH) of \u003Cstrong>(b)(4)\u003C\u002Fstrong> when RH readings ranged from \u003Cstrong>(b)(4)\u003C\u002Fstrong> during the preconditioning product phase, exceeding the allowable upper RH limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>&nbsp; &nbsp; o Your firm reported this RH protocol deviation as part of the 2022 requalification. However, your firm concluded: “…the re-qualification using dunnage devices has no effect on finished goods and no immediate actions are needed. There is no impact to sterility assurance of EO devices due to this event.” This conclusion was reached without an adequate investigation into the failed re-validation and determination of the root causes of the failure.\u003C\u002Fp>\u003Cp>• The 2023 requalification of the EO cycle \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Vessel # 1 and Vessel #2 (\u003Cstrong>(b)(4)\u003C\u002Fstrong>-0009433) approved by your firm on March 15, 2024, failed to meet your firm’s predetermined acceptance criteria that all internal and external biological indicators (BI) were required to be negative for growth as one external process challenge devices (PCD) resulted in positive growth. Further, the RH specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was not met as RH readings ranged from \u003Cstrong>(b)(4)\u003C\u002Fstrong> during the preconditioning product phase, exceeding the allowable upper RH limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>&nbsp; &nbsp; o As a result of the 2023 requalification failures, Vessel #2 was disqualified for EO cycle \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your firm continues to use Vessel #1 which also failed to meet the same EO requalification predetermined acceptance criteria (RH) that caused your firm to disqualify Vessel #2 and similar conclusions used during the 2022 deviation report were again restated in 2023 to justify continued use of Vessel #1.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated NC-001007 on June 7, 2024 which was later escalated to CAPA-00179 on June 11, 2024 to address, in part, annual parameter failures associated with EO cycle \u003Cstrong>(b)(4)\u003C\u002Fstrong> including revisions made to your \u003Cem>Annual EO Revalidation \u003C\u002Fem>\u003Cstrong>(b)(4)\u003C\u002Fstrong> work instruction (WI-10007) and planned performance of requalification for EO cycle \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the current year utilizing the updated WI. However, this requalification has not occurred as it has a target date of December 31, 2024.\u003C\u002Fp>\u003Cp>Additionally, at your Princeton, NJ location, your firm initiated a Supplier Change Request (SCAR #NC-101873) to change the pouch sealing machine to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which supplies pouches (product number \u003Cstrong>(b)(4)\u003C\u002Fstrong>) to your firm’s Le Locle, Switzerland facility for packaging of sterile medical devices after detection that the pouch was opened on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sealing side. Investigation into the seal strength caused your supplier to perform a revalidation of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to challenge the ability to produce product that meets specifications.\u003C\u002Fp>\u003Cp>In the performance qualification protocol performed by your supplier (\u003Cstrong>(b)(4)\u003C\u002Fstrong>-24010), a minimum acceptable seal value lower specification limit (LSL) of \u003Cstrong>(b)(4)\u003C\u002Fstrong> lb\u002Fin was utilized. In your Retrospective Validation Report for Bactiseal Pouch Supplier Sealer Performance (Document ENG-199915-MEMO) the seal strength lower spec. is listed as \u003Cstrong>(b)(4)\u003C\u002Fstrong> lbf\u002Fin. However, the validation qualification report for Package Performance and Package Stability Study for Bactiseal EVD (applicable to your Le Locle, Switzerland and Mansfield, MA locations) concluded that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> minimum specification will meet the \u003Cstrong>(b)(4)\u003C\u002Fstrong> lb\u002Fin post sterilization requirement specified in the BSN 868-5 standard. This validation qualification report was performed in 2021 prior to the change to your supplier’s \u003Cstrong>(b)(4)\u003C\u002Fstrong> and does not account for your supplier’s use of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> lb\u002Fin LSL.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated CAPA-00146 on September 6, 2024 to address the lack of consistent assessment of validations when changes occur, as well as state a commitment to: update your product and process change decisions tree; create a global procedure for assessment of supplier changes; obsolete your supplier change process at Mansfield and Le Locle; and perform a retrospective review of Integra supplier change procedures. However, your firm continues to implement a number of corrective actions that will not be completed until January 2025\u003C\u002Fp>\u003Cp>6. Failure to establish and maintain procedures to prevent contamination of equipment or product by substances that could reasonably be expected to have an adverse effect on product quality, as required by 21 CFR 820.70(e).\u003C\u002Fp>\u003Cp>For example, the Controlled Environment and Cleanroom Operating and Monitoring Procedure (Rev: 065, Effective Date: 20 April 2021) utilized at your Mansfield, MA location was not followed. Multiple (18) viable and non-viable particulate environmental excursion results, occurring from January 2023 to April 2024, for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanroom were observed near a \u003Cstrong>(b)(4)\u003C\u002Fstrong>, equipment identification #\u003Cstrong>(b)(4)\u003C\u002Fstrong>) located in room \u003Cstrong>(b)(4)\u003C\u002Fstrong>. As a result, your firm updated the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning procedure to “\u003Cem>include routine cleaning of the locations which had visible particulate accumulation on the surface\u003C\u002Fem>” and determined the risk to product quality as “Low – no product impact” without adequate investigation or a risk-based assessment to evaluate product impact. Several devices, including surgical patties, are manufactured using the identified \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine, where the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanroom failed your firm’s pre-established alert and action limits.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated CAPA-100180 on June 11, 2024 to address updates needed to address this observation. We also acknowledge that your firm has updated your non-routine cleaning frequency for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine, plans to complete a Health Hazard Evaluation, and develop a contamination control plan. However, your firm continues to implement these corrective actions that have a target date in January 2025.\u003C\u002Fp>\u003Cp>For your Plainsboro, NJ location, during review of Particulate Air Sampling records (CNS-G-630A), it was observed that your firm set the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanroom action limit at \u003Cstrong>(b)(4)\u003C\u002Fstrong> um sized particles per cubic meter. This action limit selected is the maximum allowance specified in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> standard. Your firm’s action limit being set at the maximum allowable level does not provide an opportunity to take action before exceeding the specification.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated CAPA-00151 on September 5, 2024 to address updates needed to resolve the observation. We also acknowledge that your firm plans to establish alert\u002Faction limits for \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanrooms that allow proactive actions to prevent exceeding particulate specifications along with planned changes to associated procedures. However, these corrective actions have not been implemented as a number of corrective actions have target completion dates in February 2025.\u003C\u002Fp>\u003Cp>7. Failure to validate with a high degree of assurance, a process whose results cannot be fully verified by subsequent inspection and test, as required by 21 CFR § 820.75(a).\u003C\u002Fp>\u003Cp>Specifically, your firm failed to follow your corporate-wide procedure for Process Validation (GSOP-738; Rev 007), in that section 5.2.5 states a protocol may be generated for each qualification, and section 5.2.6.6 states a qualification report is required for each qualification activity.\u003C\u002Fp>\u003Cp>For example, at your Plainsboro, NJ location, your firm’s validation of procedure CMC-AH-10, (determination of bacterial endotoxins in Integra products, \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> using the \u003Cstrong>(b)(4)\u003C\u002Fstrong>), lacks a validation protocol and validation report. The validation for the inhibition and enhancement testing for Limulus Amebocyte Lysate (LAL) was performed in 2004 under a previous process validation procedure (MD-029; obsoleted 5\u002F5\u002F2022). The only record for validation of this LAL test were results from Inhibition\u002FEnhancement Testing – \u003Cstrong>(b)(4)\u003C\u002Fstrong> performed on four lots of INTEGRA Dermal Regeneration Template (IRDT)-TS \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of IDRT have been produced since 12\u002F1\u002F2004.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated CAPA-00136 on September 10, 2024 to address the lack of protocol and report for the validation of inhibition\u002Fenhancement Testing of LAL, as well as a commitment to \u003Cstrong>(b)(4)\u003C\u002Fstrong> validations for all Collagen Manufacturing Center (CMC) products, revisions to your CMC-AH-10 test method, and revisions to your change control procedures. However, your firm continues to implement a number of corrective actions that will not be completed until January 2025.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Assistant Director Gina Brackett at CDRHWarningLetterResponses@fda.hhs.gov. Please include in the subject line \u003Cstrong>CMS Case 698850\u003C\u002Fstrong> when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan, Consumer Safety Officer at sean.moynihan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>RDML Sean M. Boyd, MPH, USPHS\u003Cbr>Director Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality&nbsp;&nbsp;\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Jan De Witte\n\nRecipient Title\n\nPresident and CEO\n\nIntegra LifeSciences Corporation\n\n1100 Campus Road\n\nPrinceton, NJ 08540\n\nUnited States\n\n(b)(4)@integralife.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 698850\nDecember 19, 2024\nDear Mr. DeWitte:\nThe United States Food and Drug Administration (FDA) conducted the following inspections of your firm’s medical device facilities:\nIntegra LifeSciences Corporation, located at 11 Cabot Blvd, Mansfield, MA, FEI 3014334038, from March 12, 2024 through June 5, 2024\nIntegra LifeSciences Corporation, located at 105 And 109 Morgan Ln, Plainsboro, NJ, FEI 1121308, from April 9, 2024 through August 22, 2024\nIntegra LifeSciences Corporation, located at 1100 Campus Rd, Princeton, NJ, FEI 3003418325, from March 12, 2034 through August 22, 2024\nDuring these inspections, FDA investigators and a microbiologist determined that the above firms manufacture a variety of neurological and neurosurgical devices, including but not limited to, cranial perforators, disposable cottonoid patties and strips as well as collagen based medical devices, that are used for wound care, soft tissue repair and reconstruction surgery. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nThe above inspections revealed that the above devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received responses from Jeffrey Caldwell, Vice President, Quality Operations dated June 27, 2024, August 27, 2024, and October 25, 2024 concerning our investigator’s and microbiologist’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm’s Mansfield, MA location on June 5, 2024.\nWe received responses from Brenda Romero, Director, Quality Operations, CMC dated September 27, 2024 and December 5, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm’s Plainsboro, NJ location on August 22, 2024.\nWe received responses from Jessica Smith, Corporate Vice President, Chief Regulatory Officer, and interim Chief Quality Officer dated September 13, 2024 and from Lacey Gigante, Sr. Director, CAPA & Compliance November 15, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm’s Princeton, NJ location on August 22, 2024.\nWe address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures to control product that does not conform to specified requirements. The procedures shall address the identification, documentation, evaluation, segregation, and disposition of nonconforming product. The evaluation of nonconformance shall include a determination of the need for an investigation and notification of the persons or organizations responsible for the nonconformance. The evaluation and any investigation shall be documented, as required by 21 CFR § 820.90(a).\nSpecifically, during an inspection of your Mansfield, MA location, a review of 4 non-conforming reports from October 2022 through June 2023 (NC-101352, NC-101446, NC-101628, and NC-101642) were opened due to Out of Specification (OOS) endotoxin results on three separate lots of surgical patties and one lot of Duraform. In the above instances, after the laboratory investigation concluded there was no assignable laboratory error or root cause, your firm retested the lots, even though your Pyrogen Testing procedure, MPS-PC340, did not specify that a retest was allowed. Your firm then released the above referenced lots without conducting a complete investigation of the manufacturing processes, as required by your Non-Conformance procedure, GSOP-773 and MPS-PC340.\nWe reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated a recall of Duraform, lot CT007694 on September 6, 2024 as well as a recall of multiple lots of surgical patties and strips manufactured between 2022 and 2023 on September 20, 2024. However, your firm continues to implement a number of corrective actions at your Mansfield, MA facility that will not be completed until May 2025.\n2. Failure to establish and maintain procedures for acceptance activities. Acceptance activities include inspections, tests, or other verification activities; as required by 21 CFR § 820.80(a).\nSpecifically, your Plainsboro, NJ location utilizes procedure CMC-MB-049 “Determination of Endotoxin in (b)(4) Product Using the (b)(4) Methods” to determine the bacterial endotoxin concentration in products manufactured at the Integra LifeSciences Collagen Manufacturing Center (CMC), Buildings (b)(4) and (b)(4), including (b)(4). According to section 9.6.3.3 of this procedure, “the Coefficient of Variation (CV%) for each pair of standard series samples must be less than (b)(4)” for the overall test to be considered valid. However, during our inspection we observed that ten of fifty-two tests conducted in 2023 failed due to the CV% exceeding the (b)(4) limit. These ten tests were observed to be repeatedly retested until the CV% fell below (b)(4). For example, endotoxin test (LAL-24-2012) and its two subsequent retests (LAL-24-0012 Retest, LAL-24-0012 Retest 2) all failed to meet CV% criteria. It was then retested on a different day under a new ID (LAL-24-0013) and finally passed on the fourth attempt (LAL-24-0013 Retest 3). Your firm’s microbiology manager attributed the CV% failures to low endotoxin concentration in the controls. Additionally, your CMC-MB-049 procedure does not specify the circumstances under which a retest could be performed or which result should be utilized if a retest was conducted.\nWe reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated three CAPAs (CAPA-00133, CAPA-00134, and CAPA-00135) to address the observations. As part of these CAPAs, we acknowledge that your firm has performed a statistical assessment of historical reagent qualification data for CV% in which you determined that the appropriate CV% for the (b)(4) EU\u002FmL standard concentration would be (b)(4)% and made updates to affected procedures, including CMC-MB-049. However, verification of the effectiveness of the corrective actions are still ongoing with a target date of June 2025. Please provide the results of your firm’s planned 6-month effectiveness check when it becomes available.\n3. Failure to establish and maintain procedures for finished device acceptance to ensure that each production run, lot, or batch of finished devices meets acceptance criteria, as required by 21 CFR § 820.80(d).\nSpecifically, your Mansfield, MA location utilizes MPS-PC340, Preparing Products for Pyrogen Testing (Rev: 068, Effective Date: 30Mar2023) to describe the procedures and materials needed to prepare test samples for pyrogenicity and how to investigate results that exceed acceptable criteria. However, review of this procedure determined it lacks the following requirements to ensure devices meet established endotoxins specifications for device sterility prior to release. For example,\n Adequate instructions for OOS laboratory investigations where the original endotoxins results are determined to be valid because no laboratory error or assignable cause was found.\n Documentation of how many times the device lot or device extract may be re- analyzed or retested during the investigation after an OOS result is reported.\n Lack of details regarding sample selection to ensure samples are representative of the entire lot to account for endotoxins not evenly distributed within the lot.\n No requirement to include documentation of endotoxin test result units (EU\u002Fml or EU\u002Fdevice) on the Post-Sterile Release section of your Device History Records.\nFor example, verification of Pyrogen Lab Results receipt for Lot # 7260687 of Product Code (b)(4) lists the Lab Result as “(b)(4).” The Endotoxin Action Limit for this product code is (b)(4) EU\u002FDevice. Your Bacterial Endotoxin Test Final Report (Study Number 1621708-S01), dated June 15, 2023 concluded that the pooled test articles for Lot # 7260687 “exceeded the endotoxin limit of not more than (b)(4) EU\u002Fdevice.”\nWe reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated NC-001411 on June 7, 2024 and CAPA-100183 on June 11, 2024 to address updates needed to the procedural requirements, updates to DHRs so that BET result units are accurately recorded among other actions. However, your firm continues to implement a number of corrective actions that will not be completed until March 2025.\n4. Failure to establish and maintain procedures for corrective and preventive action, as required by 21 § CFR 820.100(a). For example,\nDuring the inspection of the Princeton, NJ corporate headquarters, your Corrective and Preventive Action (CAPA) Process (GSOP-758; Rev 007), specifically, Section 7.1, describes the process of CAPA Escalation. Section 7.1.2.3 of GSOP-758 describes when a decision is made to not initiate a CAPA, including documentation of the justification for not initiating a CAPA on Form GSOP-758A (CAPA Escalation Decision Form). A review of quality data sources over individual Integra sites, including corrective and preventive actions (CAPAs) and quality plans (QPs) taken at numerous Integra firm locations revealed that site specific CAPAs are not evaluated for escalation to corporate wide CAPAs.\nFor example, CAPA 23-008 opened on April 7, 2023 at the (b)(4) manufacturing location in (b)(4) was related to endotoxin testing at that location. Endotoxin testing is performed at other locations, including collagen manufacturing in Plainsboro, NJ and neurological manufacturing in Mansfield, MA. The decision and justification to not escalate endotoxin testing to a corporate wide CAPA was not documented.\nAdditionally, per Section 5.2.1 of the Quality Objectives & Quality Planning document (GSOP-763; Rev. 003) “quality planning is not used to investigate or correct actual or potential problems or concerns arising from the QMS or its data sources.” However, during our inspections, you provided several quality plans that were being utilized for investigating or correcting actual and potential problems with the quality systems. The GSOP-763 procedure used for quality planning does not include pertinent sections required for corrective and preventive actions such as: investigating the cause of nonconformities, identifying the actions needed to correct and prevent recurrence, and verifying or validating the action to ensure it is effective. These sections are found within the CAPA procedure GSOP-758. At the time of our inspections, CAPAs had not been opened to address these issues. Examples of quality plans currently being used to correct problems with the quality system are:\n• At your Princeton, NJ location\no QP-2023-12, Quality Plan for Assessing Endotoxin Program Compliance, initiated on March 25, 2024 to assess endotoxin issues across Integra organizations. This quality plan lists a target completion date for site-specific gap assessments as 12\u002F31\u002F2026 and the target due date for developing an action plan to close and\u002For mitigate any identified compliance gaps as 6\u002F30\u002F2027.\n• At your Plainsboro, NJ location\no QP-2023-02, Quality Plan for the Closure of Overdue SCARs at the Collagen Manufacturing Center, initiated on December 7, 2023 to document the closure of overdue SCARs at the Collagen Manufacturing Center (CMC). Eleven SCARs were identified as overdue in section 2.2 of this document.\n• At your Mansfield, MA location\no QP-20-001, Quality Plan for CerebroFlo EVD Catheter design history file remediation initiated on April 9, 2020, to address 30 observations found during a third-party review of the CerebroFlo EVD catheter design project.\nWe reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated several CAPAs at multiple sites, including a corporate-wide CAPA-00143 on September 6, 2024 to address the extension of CAPAs and Quality Plans across multiple Integra locations including planned implementation of a CAPA escalation decision tree and form by December 15, 2024; planned review of all CAPAs initiated at Integra corporate and all manufacturing sites since November 2, 2022; and planned updates to GSOP-758 to require an evaluation of each CAPA to determine whether it may be applicable to multiple manufacturing sites. However, your firm continues to implement corrective actions that will not be completed until November 2025 when verification of effectiveness is targeted to be completed.\n5. Failure to review and evaluate process changes and deviations and perform revalidation when changes or process deviations occur, as required by 21 CFR § 820.75(c).\nFor example, at your Mansfield, MA location, your firm failed to assess the impact of annual sterilization requalification parameter failures for Ethylene Oxide (EO) cycle #(b)(4) used to demonstrate a continued sterility assurance level of (b)(4) EO sterilization is performed by (b)(4). EO cycle #(b)(4) is used sterilization of several devices manufactured at Mansfield, MA including neurological surgical patties. For example,\n• On December 2, 2020, a deviation occurred with eight temperature sensors recording temperatures below the minimum (b)(4) degrees Fahrenheit for the product temperature during the EO exposure dwell phase, failing to meet the predetermined validation acceptance criteria of (b)(4).\no Your firm failed to investigate the cause of the temperature failure and the potential effect on the EO cycle for routine sterilization.\n• The 2022 requalification of the EO cycle (b)(4) for Vessel #1 and Vessel # 2, ((b)(4)-0007898) approved by your firm on November 23, 2022, exceeded your firm’s predetermined acceptance criteria for product load relative humidity (RH) of (b)(4) when RH readings ranged from (b)(4) during the preconditioning product phase, exceeding the allowable upper RH limit of (b)(4).\no Your firm reported this RH protocol deviation as part of the 2022 requalification. However, your firm concluded: “…the re-qualification using dunnage devices has no effect on finished goods and no immediate actions are needed. There is no impact to sterility assurance of EO devices due to this event.” This conclusion was reached without an adequate investigation into the failed re-validation and determination of the root causes of the failure.\n• The 2023 requalification of the EO cycle (b)(4) for Vessel # 1 and Vessel #2 ((b)(4)-0009433) approved by your firm on March 15, 2024, failed to meet your firm’s predetermined acceptance criteria that all internal and external biological indicators (BI) were required to be negative for growth as one external process challenge devices (PCD) resulted in positive growth. Further, the RH specification of (b)(4) was not met as RH readings ranged from (b)(4) during the preconditioning product phase, exceeding the allowable upper RH limit of (b)(4).\no As a result of the 2023 requalification failures, Vessel #2 was disqualified for EO cycle (b)(4). However, your firm continues to use Vessel #1 which also failed to meet the same EO requalification predetermined acceptance criteria (RH) that caused your firm to disqualify Vessel #2 and similar conclusions used during the 2022 deviation report were again restated in 2023 to justify continued use of Vessel #1.\nWe reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated NC-001007 on June 7, 2024 which was later escalated to CAPA-00179 on June 11, 2024 to address, in part, annual parameter failures associated with EO cycle (b)(4) including revisions made to your Annual EO Revalidation (b)(4) work instruction (WI-10007) and planned performance of requalification for EO cycle (b)(4) for the current year utilizing the updated WI. However, this requalification has not occurred as it has a target date of December 31, 2024.\nAdditionally, at your Princeton, NJ location, your firm initiated a Supplier Change Request (SCAR #NC-101873) to change the pouch sealing machine to (b)(4), which supplies pouches (product number (b)(4)) to your firm’s Le Locle, Switzerland facility for packaging of sterile medical devices after detection that the pouch was opened on the (b)(4) sealing side. Investigation into the seal strength caused your supplier to perform a revalidation of (b)(4) to challenge the ability to produce product that meets specifications.\nIn the performance qualification protocol performed by your supplier ((b)(4)-24010), a minimum acceptable seal value lower specification limit (LSL) of (b)(4) lb\u002Fin was utilized. In your Retrospective Validation Report for Bactiseal Pouch Supplier Sealer Performance (Document ENG-199915-MEMO) the seal strength lower spec. is listed as (b)(4) lbf\u002Fin. However, the validation qualification report for Package Performance and Package Stability Study for Bactiseal EVD (applicable to your Le Locle, Switzerland and Mansfield, MA locations) concluded that the (b)(4) minimum specification will meet the (b)(4) lb\u002Fin post sterilization requirement specified in the BSN 868-5 standard. This validation qualification report was performed in 2021 prior to the change to your supplier’s (b)(4) and does not account for your supplier’s use of a (b)(4) lb\u002Fin LSL.\nWe reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated CAPA-00146 on September 6, 2024 to address the lack of consistent assessment of validations when changes occur, as well as state a commitment to: update your product and process change decisions tree; create a global procedure for assessment of supplier changes; obsolete your supplier change process at Mansfield and Le Locle; and perform a retrospective review of Integra supplier change procedures. However, your firm continues to implement a number of corrective actions that will not be completed until January 2025\n6. Failure to establish and maintain procedures to prevent contamination of equipment or product by substances that could reasonably be expected to have an adverse effect on product quality, as required by 21 CFR 820.70(e).\nFor example, the Controlled Environment and Cleanroom Operating and Monitoring Procedure (Rev: 065, Effective Date: 20 April 2021) utilized at your Mansfield, MA location was not followed. Multiple (18) viable and non-viable particulate environmental excursion results, occurring from January 2023 to April 2024, for your (b)(4) cleanroom were observed near a (b)(4), equipment identification #(b)(4)) located in room (b)(4). As a result, your firm updated the (b)(4) cleaning procedure to “include routine cleaning of the locations which had visible particulate accumulation on the surface” and determined the risk to product quality as “Low – no product impact” without adequate investigation or a risk-based assessment to evaluate product impact. Several devices, including surgical patties, are manufactured using the identified (b)(4) machine, where the (b)(4) cleanroom failed your firm’s pre-established alert and action limits.\nWe reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated CAPA-100180 on June 11, 2024 to address updates needed to address this observation. We also acknowledge that your firm has updated your non-routine cleaning frequency for the (b)(4) machine, plans to complete a Health Hazard Evaluation, and develop a contamination control plan. However, your firm continues to implement these corrective actions that have a target date in January 2025.\nFor your Plainsboro, NJ location, during review of Particulate Air Sampling records (CNS-G-630A), it was observed that your firm set the (b)(4) cleanroom action limit at (b)(4) um sized particles per cubic meter. This action limit selected is the maximum allowance specified in the (b)(4) standard. Your firm’s action limit being set at the maximum allowable level does not provide an opportunity to take action before exceeding the specification.\nWe reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated CAPA-00151 on September 5, 2024 to address updates needed to resolve the observation. We also acknowledge that your firm plans to establish alert\u002Faction limits for (b)(4) cleanrooms that allow proactive actions to prevent exceeding particulate specifications along with planned changes to associated procedures. However, these corrective actions have not been implemented as a number of corrective actions have target completion dates in February 2025.\n7. Failure to validate with a high degree of assurance, a process whose results cannot be fully verified by subsequent inspection and test, as required by 21 CFR § 820.75(a).\nSpecifically, your firm failed to follow your corporate-wide procedure for Process Validation (GSOP-738; Rev 007), in that section 5.2.5 states a protocol may be generated for each qualification, and section 5.2.6.6 states a qualification report is required for each qualification activity.\nFor example, at your Plainsboro, NJ location, your firm’s validation of procedure CMC-AH-10, (determination of bacterial endotoxins in Integra products, (b)(4) and (b)(4) using the (b)(4)), lacks a validation protocol and validation report. The validation for the inhibition and enhancement testing for Limulus Amebocyte Lysate (LAL) was performed in 2004 under a previous process validation procedure (MD-029; obsoleted 5\u002F5\u002F2022). The only record for validation of this LAL test were results from Inhibition\u002FEnhancement Testing – (b)(4) performed on four lots of INTEGRA Dermal Regeneration Template (IRDT)-TS (b)(4). Approximately (b)(4) lots of IDRT have been produced since 12\u002F1\u002F2004.\nWe reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated CAPA-00136 on September 10, 2024 to address the lack of protocol and report for the validation of inhibition\u002Fenhancement Testing of LAL, as well as a commitment to (b)(4) validations for all Collagen Manufacturing Center (CMC) products, revisions to your CMC-AH-10 test method, and revisions to your change control procedures. However, your firm continues to implement a number of corrective actions that will not be completed until January 2025.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Assistant Director Gina Brackett at CDRHWarningLetterResponses@fda.hhs.gov. Please include in the subject line CMS Case 698850 when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan, Consumer Safety Officer at sean.moynihan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nRDML Sean M. Boyd, MPH, USPHS\nDirector Office of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Integra LifeSciences Corporation","integra-lifesciences-corporation-698850-12192024","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintegra-lifesciences-corporation-698850-12192024","2026-10-26T08:08:59.635431+00:00","Warning Letter","Issued","2025-01-14","698850","Medical Devices","Mr. Jan De Witte","2026-08-19T17:04:50.521+00:00","VIA Electronic Mail","2024-12-19",{"id":32,"raw":33,"subject":12,"body_html":38,"body_text":39,"firm_name":16,"letter_id":40,"created_at":41,"fei_number":19,"letter_url":42,"updated_at":43,"action_type":22,"case_status":23,"posted_date":44,"marcs_cms_no":45,"product_type":26,"closeout_date":19,"issuing_office":46,"recipient_name":27,"body_fetched_at":47,"delivery_method":48,"recipient_title":19,"reference_number":19,"action_taken_date":49,"medical_device_id":19,"response_letter_date":19},1934,[34,35,36,37,12,13,13,13],"\u003Ctime datetime=\"2023-08-15T13:20:00Z\">08\u002F15\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-07-17T04:00:00Z\">07\u002F17\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintegra-lifesciences-corporation-660960-07172023\">Integra LifeSciences Corporation\u003C\u002Fa>"," Division of Medical Device and Radiological Health Division I","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jan De Witte\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Integra LifeSciences Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1100 Campus Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Princeton\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08540\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jan.dewitte@integralife.com\"> jan.dewitte@integralife.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Medical Device and Radiological Health Division I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 660960\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 17, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. DeWitte:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations, TEI Biosciences, Inc., an Integra LifeSciences Company, located at 7 Elkins Street, Boston, MA, from March 1 through May 17, 2023. During the inspection, FDA investigators determined that your firm is a medical device manufacturer of collagen based medical devices, that are used for wound care, soft tissue repair and reconstruction surgery, including Durepair. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that the above devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received your response dated June 8, 2023 from Susan Krause, Corporate Vice President, Chief Quality Officer, Integra Lifesciences Corporation, which responded to the Form FDA 483, List of Inspectional Observations issued to your firm on May 17, 2023. On May 23, 2023, our office also confirmed that TEI initiated a recall of all finished goods manufactured within expiry from March 1, 2018 through May 22, 2023, (RES 92481). We also understand that you have committed to not distributing product until the TEI Bioscience site is operating in substantial conformity with Quality System regulations (QSR). We address your June 8, 2023 response below.\u003C\u002Fp>\n\n\u003Cp>These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). Specifically:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On June 19, 2019, your firm released a lot of Durepair,# 1904005 for distribution that indicated a bacterial endotoxin (BET) result of 9.98 EU\u002FDevice. This result exceeded your acceptance criteria of \u003Cstrong>(b)(4)\u003C\u002Fstrong> device as specified in your procedure, QCP-037 - Performance of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;Endotoxin Assay. The device history record for this lot of product showed that the lot was approved and released by your firm without an investigation or product risk assessment for the BET result that was out of specification (OOS).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s response and conclude it is not adequate. Your response indicated that NC 23-042 was initiated during the inspection when the above Durepair OOS result was brought to your attention. On May 30, 2023, your firm determined the above OOS result was the result of a transcription error and the 9.98 EU result was for a different lot of product where this was an acceptable result (specification was \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Your response indicated that CAPA 23-026 was opened to address the above nonconformance deficiencies, yet you have not provided a copy of the CAPA nor have you identified all necessary corrective actions to demonstrate that your quality system will ensure controls are in place to prevent the release of non-conforming product. We remain concerned that your quality system will be capable of identifying similar OOS errors when you resume operations and will prevent the release of non-conforming products.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain procedures for implementing corrective and preventive actions, including requirements for analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a)(1). Specifically:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On October 20, 2022, your firm received an internal complaint that alleged quality issues in \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing areas including your \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection process, bacterial endotoxin testing, bovine hide\u002Fskin thickness measurements, and control of sterilized devices. As the result of your initial investigation, your firm initiated a production hold on December 14, 2022 and also placed \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of product on hold. You initiated a CAPA to address the \u003Cstrong>(b)(4)\u003C\u002Fstrong> issue, however, CAPAs were not opened to address the remaining \u003Cstrong>(b)(4)\u003C\u002Fstrong> areas of concern, including endotoxin issues. Your CAPA procedure, GSOP-758, rev 005, indicates that “CAPA investigations and any corrections, corrective and\u002F or preventive actions should be \u003Cstrong>(b)(4)\u003C\u002Fstrong>”.\u003C\u002Fli>\n\t\u003Cli>During the inspection, you initiated a health hazard evaluation, 2023-HHE-005 to address the endotoxin concerns and the potential health risk. This HHE, completed on April 12, 2023, was not comprehensive and did not include all complaints that may have been associated with this issue. For example, two complaints of meningitis, complaint #’s 198786 and 198790, associated with your Durepair product were not included in your initial HHE assessment that concluded a field action was not recommended. Your HHE SOP, GSOP-908, rev 015 indicates that the criteria for a HHE initiation would be when “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”.\u003C\u002Fli>\n\t\u003Cli>Your firm failed to \u003Cstrong>(b)(4)\u003C\u002Fstrong> as required per your procedure, GSOP-801 rev 3, \u003Cstrong>(b)(4)\u003C\u002Fstrong>; Rev 03. On December 14, 2022, a hold was placed on \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots identified in the complaint but failed to identify the potential impact on \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots manufactured during the same time frame.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s response and conclude it is not adequate. We are aware that this is a repeat CAPA deficiency from our 2019 Warning Letter to this facility. Your response indicated that \u003Cstrong>(b)(4)\u003C\u002Fstrong> CAPAs will be initiated to address the above deficiency, however you have not yet identified all necessary corrective actions, nor have you provided a copy of your CAPAs to ensure they will be comprehensive and capable of addressing the systemic issues that have been identified. We understand that you have taken a series of corrective actions, including a recall and production hold, however your response does not indicate how you will prevent such errors from recurring when you resume operations. In response to this Warning Letter, you will need to provide evidence that an effective and sustainable CAPA system will be implemented at your firm.\u003C\u002Fp>\n\n\u003Cp>3. Failure to validate with a high degree of assurance, a process whose results cannot be fully verified by subsequent inspection and test, as required by 21 CFR 820.75(a). Specifically:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm failed to adequately validate your test method for testing bacterial endotoxin (BET) of finished medical devices, or the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used during the manufacture of these devices. Review of your BET test method validation, TMVR-009; revealed the following:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o The TMVR-009 assay reports failed to meet \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing.\u003C\u002Fp>\n\n\u003Cp> \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated January 28, 2019, excluded \u003Cstrong>(b)(4)\u003C\u002Fstrong> with “Sample Descriptions” of “Negative Control”, invalidating BET test method verification runs for product lots # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp> \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated January 2, 2019, excluded \u003Cstrong>(b)(4)\u003C\u002Fstrong> with sample descriptions “Negative Control”, invalidating BET test method verification runs for product lots # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp> \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated January 29, 2019, excluded \u003Cstrong>(b)(4)\u003C\u002Fstrong> with lot sample description “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, “Sample \u003Cstrong>(b)(4)\u003C\u002Fstrong>”, invalidating the BET test method verification for product lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>o Your BET test method protocol, section 7.4 Execution and Documentation of BET Assay, cannot be followed as written, to accurately \u003Cstrong>(b)(4)\u003C\u002Fstrong> for BET analysis of device product testing. For example, Section 7.4, step 4., states, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, the referenced table lists the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>o During routine BET testing, your firm introduced a \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in calculating the Endotoxin Limit which may cause the BET test method to be performed at \u003Cstrong>(b)(4)\u003C\u002Fstrong> to detect bacterial endotoxins. The use of this \u003Cstrong>(b)(4)\u003C\u002Fstrong> was not included in your endotoxin test method validation, TMVR-009.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm failed to adequately validate your test method for bioburden testing of finished medical devices. Review of TMVP-014, Revision 00, Test Method Validation Report for Bioburden Testing; Effective Date April 3, 2020, revealed:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o Your report failed to meet the product bioburden recovery Acceptance Criteria \u003Cstrong>(b)(4)\u003C\u002Fstrong> to monitor device \u003Cstrong>(b)(4)\u003C\u002Fstrong> bioburden loads.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm failed to adequately validate your test method for bacterial endotoxin of \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacture of your finished medical devices. Review of \u003Cstrong>(b)(4)\u003C\u002Fstrong>; Rev 00; Effective Date: April 25, 2019 revealed the following:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o For BET Report # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Run Date: 3\u002F27\u002F2019, the negative control replicate original data from \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> were excluded.\u003Cbr>\no \u003Cstrong>(b)(4)\u003C\u002Fstrong> sample and negative control results are evident on the BET analytical result printouts in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Attachment D. Your firm failed to meet \u003Cstrong>(b)(4)\u003C\u002Fstrong>, requirement, “Perform re-test for invalid assays\u002Fand or samples and document rationale as appropriate.”\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude it is not adequate at this time. Your response indicates that TEI Biosciences has outsourced all BET testing that was previously performed in-house, covering both product and \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing. We also acknowledge that corrective actions include your recent recall and production hold. However, your response also indicated that you initiated CAPA 23-028 to investigate all testing, inspection and method validations at your facility, beyond just BET and bioburden testing. We will need to review this CAPA to ensure it is comprehensive and will be effective in preventing similar failures from recurring when you resume distribution. In response to this Warning Letter, you will need to provide evidence that you have reviewed all your operations to ensure that you have validated processes in place.\u003C\u002Fp>\n\n\u003Cp>4. Failure to store devices in a manner to facilitate proper stock rotation and to assess its condition as appropriate, as required by 21 CFR 820.150(a). Specifically:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On March 2, 2023, sterile lots of implantable devices were observed by our FDA investigator on an unsecure open shelf located in the QC Quarantine area and were labeled as “non-Sterile”. Your procedure, Shipping and Receiving EBM Products for Sterilization; MBP 300-102, Rev 21, does not adequately prevent mix-ups of sterile\u002Fnon-sterile material. Section 7.1.5 states \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We are aware that a complaint received by your firm on October 20, 2022, also described an example where non-sterile product was being handled in the same area as sterile product. We acknowledge that a CAPA was not initiated at the time to address this issue and to prevent its recurrence.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s response and conclude it is not adequate. Your response indicated CAPA 23-031 has been opened to address this deficiency, however you have not yet completed your investigation, nor have you provided a copy of your CAPA. We will need to review your CAPA to ensure it is comprehensive and will be effective in preventing similar failures from recurring when you resume distribution. In response to this Warning Letter, you should provide confirmation that all proposed corrective actions are appropriate and effective.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>We are requesting that you submit to this office on the schedule below, certification by an outside expert consultant that he\u002Fshe has conducted an audit of your establishment's manufacturing and quality assurance systems relative to the requirements of the device QS regulation (21 CFR, Part 820). You should also submit a copy of the consultant's report, and certification by your establishment's Chief Executive Officer (if other than yourself) that he or she has reviewed the consultant's report and that your establishment has initiated or completed all corrections called for in the report. The initial certifications of audit and corrections and subsequent certifications of updated audits and corrections (if required) should be submitted to this office by the following dates:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Initial certifications by consultant and establishment – March 31, 2024\u003C\u002Fli>\n\t\u003Cli>Subsequent certifications – March 31, 2025 and March 31, 2026\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS # 660960 when replying. If you have any questions about the contents of this letter, please contact Compliance Officer, Karen Archdeacon at 781-587-7491 or at karen.archdeacon@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Joseph Matrisciano, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 1\u003C\u002Fp>\n\n\u003Cp>Cc: Susan Krause, Corporate Vice President, Chief Quality Officer, susan.krause@integralife.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Jan De Witte\n\nRecipient Title\n\nPresident and CEO\n\nIntegra LifeSciences Corporation\n\n1100 Campus Road\n\nPrinceton, NJ 08540\n\nUnited States\n\njan.dewitte@integralife.com\n\nIssuing Office:\n\nDivision of Medical Device and Radiological Health Division I\n\nUnited States\n\nWARNING LETTER\n\nCMS # 660960\n\nJuly 17, 2023\n\nDear Mr. DeWitte:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations, TEI Biosciences, Inc., an Integra LifeSciences Company, located at 7 Elkins Street, Boston, MA, from March 1 through May 17, 2023. During the inspection, FDA investigators determined that your firm is a medical device manufacturer of collagen based medical devices, that are used for wound care, soft tissue repair and reconstruction surgery, including Durepair. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that the above devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received your response dated June 8, 2023 from Susan Krause, Corporate Vice President, Chief Quality Officer, Integra Lifesciences Corporation, which responded to the Form FDA 483, List of Inspectional Observations issued to your firm on May 17, 2023. On May 23, 2023, our office also confirmed that TEI initiated a recall of all finished goods manufactured within expiry from March 1, 2018 through May 22, 2023, (RES 92481). We also understand that you have committed to not distributing product until the TEI Bioscience site is operating in substantial conformity with Quality System regulations (QSR). We address your June 8, 2023 response below.\n\nThese violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). Specifically:\n\nOn June 19, 2019, your firm released a lot of Durepair,# 1904005 for distribution that indicated a bacterial endotoxin (BET) result of 9.98 EU\u002FDevice. This result exceeded your acceptance criteria of (b)(4) device as specified in your procedure, QCP-037 - Performance of the (b)(4) Endotoxin Assay. The device history record for this lot of product showed that the lot was approved and released by your firm without an investigation or product risk assessment for the BET result that was out of specification (OOS).\n\nWe reviewed your firm’s response and conclude it is not adequate. Your response indicated that NC 23-042 was initiated during the inspection when the above Durepair OOS result was brought to your attention. On May 30, 2023, your firm determined the above OOS result was the result of a transcription error and the 9.98 EU result was for a different lot of product where this was an acceptable result (specification was (b)(4)). Your response indicated that CAPA 23-026 was opened to address the above nonconformance deficiencies, yet you have not provided a copy of the CAPA nor have you identified all necessary corrective actions to demonstrate that your quality system will ensure controls are in place to prevent the release of non-conforming product. We remain concerned that your quality system will be capable of identifying similar OOS errors when you resume operations and will prevent the release of non-conforming products.\n\n2. Failure to establish and maintain procedures for implementing corrective and preventive actions, including requirements for analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a)(1). Specifically:\n\nOn October 20, 2022, your firm received an internal complaint that alleged quality issues in (b)(4) manufacturing areas including your (b)(4) inspection process, bacterial endotoxin testing, bovine hide\u002Fskin thickness measurements, and control of sterilized devices. As the result of your initial investigation, your firm initiated a production hold on December 14, 2022 and also placed (b)(4) lots of product on hold. You initiated a CAPA to address the (b)(4) issue, however, CAPAs were not opened to address the remaining (b)(4) areas of concern, including endotoxin issues. Your CAPA procedure, GSOP-758, rev 005, indicates that “CAPA investigations and any corrections, corrective and\u002F or preventive actions should be (b)(4)”.\n\nDuring the inspection, you initiated a health hazard evaluation, 2023-HHE-005 to address the endotoxin concerns and the potential health risk. This HHE, completed on April 12, 2023, was not comprehensive and did not include all complaints that may have been associated with this issue. For example, two complaints of meningitis, complaint #’s 198786 and 198790, associated with your Durepair product were not included in your initial HHE assessment that concluded a field action was not recommended. Your HHE SOP, GSOP-908, rev 015 indicates that the criteria for a HHE initiation would be when “(b)(4)”.\n\nYour firm failed to (b)(4) as required per your procedure, GSOP-801 rev 3, (b)(4); Rev 03. On December 14, 2022, a hold was placed on (b)(4) lots identified in the complaint but failed to identify the potential impact on (b)(4) lots manufactured during the same time frame.\n\nWe reviewed your firm’s response and conclude it is not adequate. We are aware that this is a repeat CAPA deficiency from our 2019 Warning Letter to this facility. Your response indicated that (b)(4) CAPAs will be initiated to address the above deficiency, however you have not yet identified all necessary corrective actions, nor have you provided a copy of your CAPAs to ensure they will be comprehensive and capable of addressing the systemic issues that have been identified. We understand that you have taken a series of corrective actions, including a recall and production hold, however your response does not indicate how you will prevent such errors from recurring when you resume operations. In response to this Warning Letter, you will need to provide evidence that an effective and sustainable CAPA system will be implemented at your firm.\n\n3. Failure to validate with a high degree of assurance, a process whose results cannot be fully verified by subsequent inspection and test, as required by 21 CFR 820.75(a). Specifically:\n\nYour firm failed to adequately validate your test method for testing bacterial endotoxin (BET) of finished medical devices, or the (b)(4) used during the manufacture of these devices. Review of your BET test method validation, TMVR-009; revealed the following:\n\no The TMVR-009 assay reports failed to meet (b)(4) testing.\n\n (b)(4), dated January 28, 2019, excluded (b)(4) with “Sample Descriptions” of “Negative Control”, invalidating BET test method verification runs for product lots # (b)(4), and (b)(4).\n\n (b)(4), dated January 2, 2019, excluded (b)(4) with sample descriptions “Negative Control”, invalidating BET test method verification runs for product lots # (b)(4), and (b)(4).\n\n (b)(4), dated January 29, 2019, excluded (b)(4) with lot sample description “(b)(4)”, “Sample (b)(4)”, invalidating the BET test method verification for product lot # (b)(4).\n\no Your BET test method protocol, section 7.4 Execution and Documentation of BET Assay, cannot be followed as written, to accurately (b)(4) for BET analysis of device product testing. For example, Section 7.4, step 4., states, “(b)(4).” However, the referenced table lists the (b)(4).\n\no During routine BET testing, your firm introduced a (b)(4), in calculating the Endotoxin Limit which may cause the BET test method to be performed at (b)(4) to detect bacterial endotoxins. The use of this (b)(4) was not included in your endotoxin test method validation, TMVR-009.\n\nYour firm failed to adequately validate your test method for bioburden testing of finished medical devices. Review of TMVP-014, Revision 00, Test Method Validation Report for Bioburden Testing; Effective Date April 3, 2020, revealed:\n\no Your report failed to meet the product bioburden recovery Acceptance Criteria (b)(4) to monitor device (b)(4) bioburden loads.\n\nYour firm failed to adequately validate your test method for bacterial endotoxin of (b)(4) used in the manufacture of your finished medical devices. Review of (b)(4); Rev 00; Effective Date: April 25, 2019 revealed the following:\n\no For BET Report # (b)(4), Run Date: 3\u002F27\u002F2019, the negative control replicate original data from (b)(4) and (b)(4) were excluded.\n\no (b)(4) sample and negative control results are evident on the BET analytical result printouts in (b)(4), Attachment D. Your firm failed to meet (b)(4), requirement, “Perform re-test for invalid assays\u002Fand or samples and document rationale as appropriate.”(b)(4)\n\nWe reviewed your firm’s response and conclude it is not adequate at this time. Your response indicates that TEI Biosciences has outsourced all BET testing that was previously performed in-house, covering both product and (b)(4) testing. We also acknowledge that corrective actions include your recent recall and production hold. However, your response also indicated that you initiated CAPA 23-028 to investigate all testing, inspection and method validations at your facility, beyond just BET and bioburden testing. We will need to review this CAPA to ensure it is comprehensive and will be effective in preventing similar failures from recurring when you resume distribution. In response to this Warning Letter, you will need to provide evidence that you have reviewed all your operations to ensure that you have validated processes in place.\n\n4. Failure to store devices in a manner to facilitate proper stock rotation and to assess its condition as appropriate, as required by 21 CFR 820.150(a). Specifically:\n\nOn March 2, 2023, sterile lots of implantable devices were observed by our FDA investigator on an unsecure open shelf located in the QC Quarantine area and were labeled as “non-Sterile”. Your procedure, Shipping and Receiving EBM Products for Sterilization; MBP 300-102, Rev 21, does not adequately prevent mix-ups of sterile\u002Fnon-sterile material. Section 7.1.5 states (b)(4). We are aware that a complaint received by your firm on October 20, 2022, also described an example where non-sterile product was being handled in the same area as sterile product. We acknowledge that a CAPA was not initiated at the time to address this issue and to prevent its recurrence.\n\nWe reviewed your firm’s response and conclude it is not adequate. Your response indicated CAPA 23-031 has been opened to address this deficiency, however you have not yet completed your investigation, nor have you provided a copy of your CAPA. We will need to review your CAPA to ensure it is comprehensive and will be effective in preventing similar failures from recurring when you resume distribution. In response to this Warning Letter, you should provide confirmation that all proposed corrective actions are appropriate and effective.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nWe are requesting that you submit to this office on the schedule below, certification by an outside expert consultant that he\u002Fshe has conducted an audit of your establishment's manufacturing and quality assurance systems relative to the requirements of the device QS regulation (21 CFR, Part 820). You should also submit a copy of the consultant's report, and certification by your establishment's Chief Executive Officer (if other than yourself) that he or she has reviewed the consultant's report and that your establishment has initiated or completed all corrections called for in the report. The initial certifications of audit and corrections and subsequent certifications of updated audits and corrections (if required) should be submitted to this office by the following dates:\n\nInitial certifications by consultant and establishment – March 31, 2024\n\nSubsequent certifications – March 31, 2025 and March 31, 2026\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS # 660960 when replying. If you have any questions about the contents of this letter, please contact Compliance Officer, Karen Archdeacon at 781-587-7491 or at karen.archdeacon@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nJoseph Matrisciano, Jr.\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 1\n\nCc: Susan Krause, Corporate Vice President, Chief Quality Officer, susan.krause@integralife.com","integra-lifesciences-corporation-660960-07172023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintegra-lifesciences-corporation-660960-07172023","2026-10-26T08:08:59.585662+00:00","2023-08-15","660960","Division of Medical Device and Radiological Health Division I","2026-08-20T00:47:43.014+00:00","United Parcel Service","2023-07-17",{"id":51,"raw":52,"subject":57,"body_html":58,"body_text":59,"firm_name":60,"letter_id":61,"created_at":62,"fei_number":19,"letter_url":63,"updated_at":64,"action_type":22,"case_status":23,"posted_date":65,"marcs_cms_no":66,"product_type":67,"closeout_date":19,"issuing_office":56,"recipient_name":68,"body_fetched_at":69,"delivery_method":70,"recipient_title":19,"reference_number":71,"action_taken_date":72,"medical_device_id":19,"response_letter_date":19},121,[53,54,55,56,57,13,13,13],"\u003Ctime datetime=\"2026-06-09T04:00:00Z\">06\u002F09\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-02T04:00:00Z\">06\u002F02\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzydus-lifesciences-limited-722576-06022026\">Zydus Lifesciences Limited \u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Request for Records\u002FCGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-92\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Sharvil Patel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Zydus Lifesciences Limited \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Near Vaishnodevi Circle, S. G. Highway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ahmedabad\u003C\u002Fspan> \u003Cspan>382481\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gujarat\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-92\u003C\u002Fp>\u003Cp>June 2, 2026\u003C\u002Fp>\u003Cp>Dear Dr. Patel:\u003C\u002Fp>\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of prescription drug products. FDA has reviewed the records you submitted in response to our November 7, 2025 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Zydus Lifesciences Limited, FEI 3005430968, at Village Swaraj Majra, P.O. Baddi, Tehsil-Nalagarh, Solan Himachal Pradesh.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to withhold from use each lot of components, drug product containers, and closures until the lot had been sampled, tested, or examined, as appropriate, and failed to test samples for conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures prescription \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products containing talc. \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP is composed of more than \u003Cstrong>(b)(4)\u003C\u002Fstrong>% talc. Both talc and asbestos are naturally occurring minerals that may be found in close proximity in the earth. Asbestos is a potential contaminant in talc and is a known human carcinogen when inhaled.\u003Cem>\u003Cstrong>\u003Csup>1,2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Additionally, published scientific literature dating back to the 1960s has suggested a possible association between the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> containing talc in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> area and the incidence of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, potentially linked to asbestos contamination of the talc.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> The \u003Cstrong>(b)(4)\u003C\u002Fstrong> you produce can be used on areas of the body which may be an exposure risk (e.g., inhalation or\u003Cstrong> (b)(4) \u003C\u002Fstrong>area). Your product is also labeled for use in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your drug product, \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP, is considered a higher-risk drug as it pertains to patient safety regarding asbestos contamination of talc due to the risk of inadvertent inhalation or potential use in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> area.\u003C\u002Fp>\u003Cp>You have not demonstrated that you have appropriately tested incoming talc, a drug component, used in the manufacture of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products. For example, your internal testing procedures and specifications are written in accordance with the current United States Pharmacopeia (USP) specification for absence of asbestos, however, your records do not demonstrate you are testing to current USP requirements. For asbestos testing your data refers to identification testing by Infrared (IR) Spectroscopy. Current USP absence of asbestos procedure \u003Cstrong>(b)(4)\u003C\u002Fstrong> by Infrared (IR) Spectroscopy includes the evaluation of the presence of tremolite chlorite and serpentines, through scale expansions of spectra at the required wavenumbers at \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm-\u003Csup>1\u003C\u002Fsup>, and in the range of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm-\u003Csup>1\u003C\u002Fsup> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm-\u003Csup>1\u003C\u002Fsup>. Your instrument reports for the identification spectroscopy was from \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm-\u003Csup>1\u003C\u002Fsup> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm-\u003Csup>1\u003C\u002Fsup> wavenumbers and did not include any scale expansions. Your identification spectra does not evaluate for the presence of serpentines in the range of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm-\u003Csup>1\u003C\u002Fsup> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm-\u003Csup>1\u003C\u002Fsup>. Furthermore, review of the available spectral data reveals absorption features in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm⁻¹ and \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm⁻¹ region across multiple lots, which encompasses the critical \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm⁻¹ range specified for tremolite\u002Fchlorite detection, yet no scale expansion analysis was documented in any of the analytical records as per the current USP monograph.\u003C\u002Fp>\u003Cp>As a manufacturer, you have a responsibility to sample, test, and examine, as appropriate, drug components before use in production to ensure acceptable specifications for identity, strength, quality, and purity are met. Because you have not performed appropriate testing that detects asbestos in your talc components, among other things, you failed to assure the acceptability of these drug components for use in manufacture of your drug products.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Using an independent laboratory, appropriate asbestos testing results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of talc (drug component) used in the manufacture of your drug products within expiry. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for asbestos.\u003C\u002Fli>\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, methods, and specifications. Based on this review, provide a detailed plan to remediate deficiencies and evaluate the effectiveness of corrections in your laboratory system.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for asbestos contamination. Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain asbestos. Appropriate actions could include customer notifications and drug product recalls for any contaminated lots.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products are manufactured in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not effectively exercise its authority to ensure appropriate testing is conducted. Your records submitted for talc identification testing by IR spectroscopy show that an out-of-specification (OOS) wavenumber result was removed from an infrared instrument report and multiple passing wavenumbers were added. These changes allowed a failing identification test to appear as if it met release specifications. Your QU failed in its responsibility to maintain data integrity and provide adequate oversight of testing procedures, demonstrating a lack of authority and control over critical quality decisions. Furthermore, a review of all submitted certificates of analysis for talc show a pattern of numerous wavenumbers that may be statistically unlikely and raises concerns regarding the authenticity of the reported results. Between 2022 and 2025, out of 29 approved analytical results, 21 reports have identical maxima at \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm⁻¹ across different lots and dates.\u003C\u002Fp>\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities, including responsibility for approving or rejecting all procedures or specifications impacting the identity, strength, quality, and purity of the drug product. Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>ICH Q10 Pharmaceutical Quality System\u003C\u002Fem>, as well as \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>, for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload and https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload, respectively.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Results from a comprehensive investigation into the extent of the data anomalies identified in this letter and a report including any corrective and preventative action for the investigation for drugs distributed to the United States. To aid in your investigation, you may refer to FDA’s guidance document \u003Cem>Data Integrity and Compliance with Drug CGMP: Questions and Answers\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of representative batches within expiry and their related information before the QU disposition decision\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff may also allow you to meet obligations you may have to report permanent discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(a). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Zydus Lifesciences Limited, FEI 3005430968, at Village Swaraj Majra, P.O. Baddi, Tehsil-Nalagarh, Solan Himachal Pradesh into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Specify what you have done to address any violations and to prevent their recurrence. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3005430968 and ATTN: Nancy Espinal.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>CC: Mr. Prashant Sharma\u003Cbr>Chief Technical Officer\u003Cbr>Zydus Lifesciences Limited\u003Cbr>Village Swaraj Majra,\u003Cbr>P.O. Baddi, Tehsil-Nalagarh\u003Cbr>Solan Himachal Pradesh 173205 India\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Zydus Pharmaceuticals (USA) Inc.\u003Cbr>Mr. Srinivas Gurram (Srini)\u003Cbr>Senior Vice President - Head of RA and CQA lead -Americas,\u003Cbr>73-B, Route 31 North\u003Cbr>Pennington, NJ 08534\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> https:\u002F\u002Fwww.cancer.gov\u002Fabout-cancer\u002Fcauses-prevention\u002Frisk\u002Fsubstances\u002Fasbestos\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> https:\u002F\u002Fwww.atsdr.cdc.gov\u002Fasbestos\u002Fhealth-effects\u002F\u003C\u002Fp>\u003Cp>\u003Cstrong>3 \u003C\u002Fstrong>https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetic-ingredients\u002Ftalc\u003C\u002Fp>\u003Cp>\u003Cstrong>4\u003C\u002Fstrong> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\u003Cp>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-26-92\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDr. Sharvil Patel\n\nRecipient Title\n\nManaging Director\n\nZydus Lifesciences Limited\n\nNear Vaishnodevi Circle, S. G. Highway\n\nAhmedabad 382481\n\nGujarat\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-92\nJune 2, 2026\nDear Dr. Patel:\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of prescription drug products. FDA has reviewed the records you submitted in response to our November 7, 2025 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Zydus Lifesciences Limited, FEI 3005430968, at Village Swaraj Majra, P.O. Baddi, Tehsil-Nalagarh, Solan Himachal Pradesh.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\n1. Your firm failed to withhold from use each lot of components, drug product containers, and closures until the lot had been sampled, tested, or examined, as appropriate, and failed to test samples for conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84).\nYour firm manufactures prescription (b)(4) drug products containing talc. (b)(4) USP is composed of more than (b)(4)% talc. Both talc and asbestos are naturally occurring minerals that may be found in close proximity in the earth. Asbestos is a potential contaminant in talc and is a known human carcinogen when inhaled.1,2 Additionally, published scientific literature dating back to the 1960s has suggested a possible association between the use of (b)(4) containing talc in the (b)(4) area and the incidence of (b)(4), potentially linked to asbestos contamination of the talc.3 The (b)(4) you produce can be used on areas of the body which may be an exposure risk (e.g., inhalation or (b)(4) area). Your product is also labeled for use in (b)(4). Your drug product, (b)(4) USP, is considered a higher-risk drug as it pertains to patient safety regarding asbestos contamination of talc due to the risk of inadvertent inhalation or potential use in the (b)(4) area.\nYou have not demonstrated that you have appropriately tested incoming talc, a drug component, used in the manufacture of your (b)(4) drug products. For example, your internal testing procedures and specifications are written in accordance with the current United States Pharmacopeia (USP) specification for absence of asbestos, however, your records do not demonstrate you are testing to current USP requirements. For asbestos testing your data refers to identification testing by Infrared (IR) Spectroscopy. Current USP absence of asbestos procedure (b)(4) by Infrared (IR) Spectroscopy includes the evaluation of the presence of tremolite chlorite and serpentines, through scale expansions of spectra at the required wavenumbers at (b)(4) cm-1, and in the range of (b)(4) cm-1 to (b)(4) cm-1. Your instrument reports for the identification spectroscopy was from (b)(4) cm-1 to (b)(4) cm-1 wavenumbers and did not include any scale expansions. Your identification spectra does not evaluate for the presence of serpentines in the range of (b)(4) cm-1 and (b)(4) cm-1. Furthermore, review of the available spectral data reveals absorption features in the (b)(4) cm⁻¹ and (b)(4) cm⁻¹ region across multiple lots, which encompasses the critical (b)(4) cm⁻¹ range specified for tremolite\u002Fchlorite detection, yet no scale expansion analysis was documented in any of the analytical records as per the current USP monograph.\nAs a manufacturer, you have a responsibility to sample, test, and examine, as appropriate, drug components before use in production to ensure acceptable specifications for identity, strength, quality, and purity are met. Because you have not performed appropriate testing that detects asbestos in your talc components, among other things, you failed to assure the acceptability of these drug components for use in manufacture of your drug products.\nIn response to this letter, provide:\nUsing an independent laboratory, appropriate asbestos testing results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of talc (drug component) used in the manufacture of your drug products within expiry. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for asbestos.\nA comprehensive independent assessment of your laboratory practices, procedures, methods, and specifications. Based on this review, provide a detailed plan to remediate deficiencies and evaluate the effectiveness of corrections in your laboratory system.\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for asbestos contamination. Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain asbestos. Appropriate actions could include customer notifications and drug product recalls for any contaminated lots.\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products are manufactured in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) did not effectively exercise its authority to ensure appropriate testing is conducted. Your records submitted for talc identification testing by IR spectroscopy show that an out-of-specification (OOS) wavenumber result was removed from an infrared instrument report and multiple passing wavenumbers were added. These changes allowed a failing identification test to appear as if it met release specifications. Your QU failed in its responsibility to maintain data integrity and provide adequate oversight of testing procedures, demonstrating a lack of authority and control over critical quality decisions. Furthermore, a review of all submitted certificates of analysis for talc show a pattern of numerous wavenumbers that may be statistically unlikely and raises concerns regarding the authenticity of the reported results. Between 2022 and 2025, out of 29 approved analytical results, 21 reports have identical maxima at (b)(4), and (b)(4) cm⁻¹ across different lots and dates.\nYour QU is responsible for fully exercising its authority and responsibilities, including responsibility for approving or rejecting all procedures or specifications impacting the identity, strength, quality, and purity of the drug product. Your firm’s quality systems are inadequate. See FDA’s guidance document ICH Q10 Pharmaceutical Quality System, as well as Quality Systems Approach to Pharmaceutical CGMP Regulations, for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload and https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload, respectively.\nIn response to this letter, provide:\nResults from a comprehensive investigation into the extent of the data anomalies identified in this letter and a report including any corrective and preventative action for the investigation for drugs distributed to the United States. To aid in your investigation, you may refer to FDA’s guidance document Data Integrity and Compliance with Drug CGMP: Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of representative batches within expiry and their related information before the QU disposition decision\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff may also allow you to meet obligations you may have to report permanent discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(a). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Zydus Lifesciences Limited, FEI 3005430968, at Village Swaraj Majra, P.O. Baddi, Tehsil-Nalagarh, Solan Himachal Pradesh into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.4 Specify what you have done to address any violations and to prevent their recurrence. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3005430968 and ATTN: Nancy Espinal.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nCC: Mr. Prashant Sharma\nChief Technical Officer\nZydus Lifesciences Limited\nVillage Swaraj Majra,\nP.O. Baddi, Tehsil-Nalagarh\nSolan Himachal Pradesh 173205 India\nCC:\nZydus Pharmaceuticals (USA) Inc.\nMr. Srinivas Gurram (Srini)\nSenior Vice President - Head of RA and CQA lead -Americas,\n73-B, Route 31 North\nPennington, NJ 08534\n____________________\n1 https:\u002F\u002Fwww.cancer.gov\u002Fabout-cancer\u002Fcauses-prevention\u002Frisk\u002Fsubstances\u002Fasbestos\n2 https:\u002F\u002Fwww.atsdr.cdc.gov\u002Fasbestos\u002Fhealth-effects\u002F\n3 https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetic-ingredients\u002Ftalc\n4 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Zydus Lifesciences Limited","zydus-lifesciences-limited-722576-06022026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzydus-lifesciences-limited-722576-06022026","2026-10-26T08:10:40.165964+00:00","2026-06-09","722576","Drugs","Dr. Sharvil Patel","2026-08-19T04:38:28.567+00:00","VIA UPS","320-26-92","2026-06-02",{"id":74,"raw":75,"subject":79,"body_html":80,"body_text":81,"firm_name":82,"letter_id":83,"created_at":62,"fei_number":19,"letter_url":84,"updated_at":85,"action_type":22,"case_status":23,"posted_date":86,"marcs_cms_no":87,"product_type":67,"closeout_date":19,"issuing_office":56,"recipient_name":88,"body_fetched_at":89,"delivery_method":90,"recipient_title":19,"reference_number":91,"action_taken_date":92,"medical_device_id":19,"response_letter_date":19},267,[76,77,78,56,79,13,13,13],"\u003Ctime datetime=\"2026-03-17T04:00:00Z\">03\u002F17\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-03-09T04:00:00Z\">03\u002F09\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvedic-lifesciences-pvt-ltd-722446-03092026\">Vedic Lifesciences Pvt. Ltd.\u003C\u002Fa>","Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>26-HFD-45-03-02\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jayesh Chaudhary\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Vedic Lifesciences Pvt. Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>203, Morya Landmark 1, Off New Link Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Andheri West\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mumbai\u003C\u002Fspan> \u003Cspan>400053\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Maharashtra\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA Ref. No.: 26-HFD-45-03-02\u003C\u002Fp>\u003Cp>Dear Mr. Chaudhary:\u003C\u002Fp>\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between January 13 and 15, 2025. The investigators representing FDA reviewed the role of Vedic Lifesciences Pvt. Ltd. (Vedic) as the testing facility of the following nonclinical laboratory studies of the investigational drug \u003Cstrong>(b)(4)\u003C\u002Fstrong>, performed for \u003Cstrong>(b)(4)\u003C\u002Fstrong>.:\u003C\u002Fp>\u003Cp>• Study No.\u003Cstrong>(b)(4)\u003C\u002Fstrong>: “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>• Study No.\u003Cstrong>(b)(4)\u003C\u002Fstrong>: “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>• Study No.\u003Cstrong>(b)(4)\u003C\u002Fstrong>: “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003C\u002Fp>\u003Cp>This inspection was conducted as part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure the quality and integrity of study data, in accordance with Title 21 of the Code of Federal Regulations, part 58 (21 CFR 58), Good Laboratory Practice for Nonclinical Laboratory Studies.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, the FDA investigators presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your February 3, 2025, written response to the Form FDA 483.\u003C\u002Fp>\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written response dated February 3, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in 21 CFR 58 governing the conduct of nonclinical laboratory studies. We wish to emphasize the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>You failed to prepare a final report for each nonclinical laboratory study that includes, but is not limited to, the following: (1) name and address of the testing facility; (2) name of the study director and other scientists or professionals involved in the study; (3) locations where all specimens, raw data, and final reports are to be stored; and (4) study director’s signature and date [21 CFR 58.185(a)(1), 58.185(a)(10), 58.185(a)(13), and 58.185(b)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A final report must be prepared for each nonclinical laboratory study and must contain certain information, including but not limited to: (1) the name and address of the testing facility performing the study; (2) the names of the study director and other scientists or professionals involved in the study; and (3) the location where all specimens, raw data, and the final report are stored. The final report must also be signed and dated by the study director.\u003C\u002Fp>\u003Cp>You failed to adhere to these requirements. Specifically, the final reports for studies \u003Cstrong>(b)(4)\u003C\u002Fstrong> that Vedic submitted to the sponsor did not contain complete and accurate information for the above-described items that were required to be included in the final report. Examples include but are not limited to the following:\u003C\u002Fp>\u003Cp>1. The final reports for studies \u003Cstrong>(b)(4)\u003C\u002Fstrong> did not accurately identify the testing facility that performed the studies. Specifically, the testing facility that performed studies \u003Cstrong>(b)(4)\u003C\u002Fstrong> was \u003Cstrong>(b)(4) \u003C\u002Fstrong>(\u003Cstrong>(b)(4)\u003C\u002Fstrong>), and the testing facility that performed Study \u003Cstrong>(b)(4)\u003C\u002Fstrong> was \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>). However, before submitting the final reports to the sponsor, Vedic changed the final reports to falsely include the name and address of Vedic as the testing facility that performed the study.\u003C\u002Fp>\u003Cp>2. The final reports for studies \u003Cstrong>(b)(4)\u003C\u002Fstrong> did not include the correct names of the study director and other scientists or professionals involved in the study, such as the quality assurance unit (QAU) personnel. Specifically, before submitting the final reports to the sponsor, Vedic changed the final reports provided by the testing facilities that performed the study to falsely include the names of Vedic personnel as the study director or QAU personnel.\u003C\u002Fp>\u003Cp>3. The final reports for studies \u003Cstrong>(b)(4)\u003C\u002Fstrong> did not accurately identify the storage location for all specimens, raw data, and final reports. Specifically, before submitting the final reports to the sponsor, Vedic changed the final reports to falsely identify Vedic as the storage location; however, all specimens, raw data, and final reports were stored at \u003Cstrong>(b)(4)\u003C\u002Fstrong> for studies \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and at \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Study \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the testing facilities that actually performed these studies.\u003C\u002Fp>\u003Cp>4. The study directors for studies \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4) \u003C\u002Fstrong>did not sign the final reports for these studies. In accordance with 21 CFR 58.33, the study director is the individual responsible for the overall conduct of the study. For these three studies, Vedic personnel signed the final reports. However, the Vedic personnel who signed the final reports were not involved in the conduct of these studies because the studies were performed at other testing facilities. Therefore, the Vedic personnel who signed the final reports were not the individuals responsible for the overall conduct of the studies. As a result, the final reports for studies \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> did not include accurate study director signatures.\u003C\u002Fp>\u003Cp>We acknowledge that some of these findings were not included on the Form FDA 483 you received, and therefore your written response does not directly address all the violations discussed in this letter.\u003C\u002Fp>\u003Cp>However, during the inspection, the Manager of Quality Assurance stated that Vedic personnel do not serve as study directors, Vedic does not maintain study archives, Vedic has never had an animal facility, and Vedic is not a testing facility where the toxicology studies are conducted. Additionally, in your February 3, 2025, written response to the Form FDA 483, you acknowledged that Vedic outsourced Studies \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and Study \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You stated that Vedic is not a toxicology testing facility and instead operates as a liaison to prospective clients who are looking to conduct toxicology studies. You stated that it was your earlier practice to withhold from sponsors the names and contact information of partner testing facilities, study directors, QAU personnel, and archive locations to “prevent circumvention by the testing facility.” You further stated that in accordance with Vedic’s standard operating procedure (SOP), the Vedic study monitor was the single point of study control and therefore was captured as the single point of study control in the reports.\u003C\u002Fp>\u003Cp>In your written response, you stated that as part of your corrective and preventive actions, since 2022, you have stopped mentioning Vedic as a testing facility, and the details of the testing facility are now shared with the study sponsors. You also stated that you realized that your practice of listing the Vedic study monitor as the single point of study control in reports is not correct, and that the actual study director is now mentioned in final reports. You also stated that you amended the final report for Study \u003Cstrong>(b)(4)\u003C\u002Fstrong> to add the name of the correct testing facility and study director. However, since the \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing facility has closed its operations, you were unable to retrieve and amend the study reports for Studies \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, you stated that you revised your SOP for Toxicological Operations to implement the following practices: (1) The name and address of the study director will be included in the final report; (2) Vedic will be identified as the sponsor representative in the study plan and report; (3) the Vedic study monitor will sign the study plan and report; and (4) testing facility management of the GLP facility will ensure that the study director approves the study plan and report.\u003C\u002Fp>\u003Cp>While we acknowledge the actions that your site has taken and plans to take, your written response is inadequate because you did not provide sufficient details about your corrective action plan. Specifically, you did not provide sufficient details about the procedures and practices for preparing final reports that have been or will be implemented at your site to prevent similar violations in the future. For example, you did not provide details regarding any training for Vedic personnel on your updated procedures and practices. Also, the SOP that you provided does not include all the practices identified in your written response, such as including the name and address of the study director in the final report. Without this information, we cannot undertake an informed evaluation of your written response, and it is not clear whether your corrective and preventive actions will adequately ensure that ongoing and future studies will be conducted in compliance with applicable FDA regulations, including the requirements for preparing final reports.\u003C\u002Fp>\u003Cp>Failure to include accurate and complete information in the final study report raises significant concerns about the quality and integrity of the study records and data from Studies \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The final study report of an investigation is crucial to the reconstruction of the events that led to the collection and reporting of the data, and it must contain accurate and complete information regarding the conduct of the study. The information in these essential documents forms the basis for establishing scientific interpretations and conclusions and must therefore reflect all circumstances affecting the quality and integrity of the data.\u003C\u002Fp>\u003Cp>We further emphasize that nonclinical laboratory studies submitted to FDA must be accurately and completely reported in accordance with FDA regulations, to ensure the quality and integrity of study data. Your failure to provide final reports for all three studies, containing accurate and complete information that is required to be submitted to support FDA’s review of a nonclinical laboratory study, raises significant concerns about the validity and integrity of the data that were collected and submitted for these nonclinical laboratory studies.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies with the nonclinical laboratory studies of investigational drugs for which Vedic was the testing facility, as represented in final reports submitted to FDA. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action without further notice to you. If you believe that you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Should you have any questions or concerns about this letter or the inspection, please email FDA at CDER-OSI-Communications@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Your written response and any pertinent documentation should be addressed to:\u003C\u002Fp>\u003Cp>Brittany L. Garr, MPH\u003Cbr>Branch Chief\u003Cbr>Compliance Enforcement Branch\u003Cbr>Division of Enforcement and Postmarketing Safety\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003Cbr>Building 51, Room 5352\u003Cbr>10903 New Hampshire Avenue\u003Cbr>Silver Spring, MD 20993\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>{See appended electronic signature page}\u003Cbr>David C. Burrow, Pharm.D., J.D.\u003Cbr>Director\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003Cbr>\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>\u002Fs\u002F\u003Cbr>------------------------------------------------------------\u003Cbr>DAVID C BURROW\u003Cbr>03\u002F09\u002F2026 10:48:01 AM\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nReference #:\n\n26-HFD-45-03-02\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJayesh Chaudhary\n\nRecipient Title\n\nCEO\n\nVedic Lifesciences Pvt. Ltd.\n\n203, Morya Landmark 1, Off New Link Road\n\nAndheri West\n\nMumbai 400053\n\nMaharashtra\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFDA Ref. No.: 26-HFD-45-03-02\nDear Mr. Chaudhary:\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between January 13 and 15, 2025. The investigators representing FDA reviewed the role of Vedic Lifesciences Pvt. Ltd. (Vedic) as the testing facility of the following nonclinical laboratory studies of the investigational drug (b)(4), performed for (b)(4).:\n• Study No.(b)(4): “(b)(4)”\n• Study No.(b)(4): “(b)(4)”\n• Study No.(b)(4): “(b)(4)”\nThis inspection was conducted as part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure the quality and integrity of study data, in accordance with Title 21 of the Code of Federal Regulations, part 58 (21 CFR 58), Good Laboratory Practice for Nonclinical Laboratory Studies.\nAt the conclusion of the inspection, the FDA investigators presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your February 3, 2025, written response to the Form FDA 483.\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written response dated February 3, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in 21 CFR 58 governing the conduct of nonclinical laboratory studies. We wish to emphasize the following:\nYou failed to prepare a final report for each nonclinical laboratory study that includes, but is not limited to, the following: (1) name and address of the testing facility; (2) name of the study director and other scientists or professionals involved in the study; (3) locations where all specimens, raw data, and final reports are to be stored; and (4) study director’s signature and date [21 CFR 58.185(a)(1), 58.185(a)(10), 58.185(a)(13), and 58.185(b)].\nA final report must be prepared for each nonclinical laboratory study and must contain certain information, including but not limited to: (1) the name and address of the testing facility performing the study; (2) the names of the study director and other scientists or professionals involved in the study; and (3) the location where all specimens, raw data, and the final report are stored. The final report must also be signed and dated by the study director.\nYou failed to adhere to these requirements. Specifically, the final reports for studies (b)(4) that Vedic submitted to the sponsor did not contain complete and accurate information for the above-described items that were required to be included in the final report. Examples include but are not limited to the following:\n1. The final reports for studies (b)(4) did not accurately identify the testing facility that performed the studies. Specifically, the testing facility that performed studies (b)(4) was (b)(4) ((b)(4)), and the testing facility that performed Study (b)(4) was (b)(4) ((b)(4)). However, before submitting the final reports to the sponsor, Vedic changed the final reports to falsely include the name and address of Vedic as the testing facility that performed the study.\n2. The final reports for studies (b)(4) did not include the correct names of the study director and other scientists or professionals involved in the study, such as the quality assurance unit (QAU) personnel. Specifically, before submitting the final reports to the sponsor, Vedic changed the final reports provided by the testing facilities that performed the study to falsely include the names of Vedic personnel as the study director or QAU personnel.\n3. The final reports for studies (b)(4) did not accurately identify the storage location for all specimens, raw data, and final reports. Specifically, before submitting the final reports to the sponsor, Vedic changed the final reports to falsely identify Vedic as the storage location; however, all specimens, raw data, and final reports were stored at (b)(4) for studies (b)(4), and at (b)(4) for Study (b)(4), the testing facilities that actually performed these studies.\n4. The study directors for studies (b)(4) and (b)(4) did not sign the final reports for these studies. In accordance with 21 CFR 58.33, the study director is the individual responsible for the overall conduct of the study. For these three studies, Vedic personnel signed the final reports. However, the Vedic personnel who signed the final reports were not involved in the conduct of these studies because the studies were performed at other testing facilities. Therefore, the Vedic personnel who signed the final reports were not the individuals responsible for the overall conduct of the studies. As a result, the final reports for studies (b)(4), and (b)(4) did not include accurate study director signatures.\nWe acknowledge that some of these findings were not included on the Form FDA 483 you received, and therefore your written response does not directly address all the violations discussed in this letter.\nHowever, during the inspection, the Manager of Quality Assurance stated that Vedic personnel do not serve as study directors, Vedic does not maintain study archives, Vedic has never had an animal facility, and Vedic is not a testing facility where the toxicology studies are conducted. Additionally, in your February 3, 2025, written response to the Form FDA 483, you acknowledged that Vedic outsourced Studies (b)(4) to (b)(4), and Study (b)(4) to (b)(4). You stated that Vedic is not a toxicology testing facility and instead operates as a liaison to prospective clients who are looking to conduct toxicology studies. You stated that it was your earlier practice to withhold from sponsors the names and contact information of partner testing facilities, study directors, QAU personnel, and archive locations to “prevent circumvention by the testing facility.” You further stated that in accordance with Vedic’s standard operating procedure (SOP), the Vedic study monitor was the single point of study control and therefore was captured as the single point of study control in the reports.\nIn your written response, you stated that as part of your corrective and preventive actions, since 2022, you have stopped mentioning Vedic as a testing facility, and the details of the testing facility are now shared with the study sponsors. You also stated that you realized that your practice of listing the Vedic study monitor as the single point of study control in reports is not correct, and that the actual study director is now mentioned in final reports. You also stated that you amended the final report for Study (b)(4) to add the name of the correct testing facility and study director. However, since the (b)(4) testing facility has closed its operations, you were unable to retrieve and amend the study reports for Studies (b)(4). Additionally, you stated that you revised your SOP for Toxicological Operations to implement the following practices: (1) The name and address of the study director will be included in the final report; (2) Vedic will be identified as the sponsor representative in the study plan and report; (3) the Vedic study monitor will sign the study plan and report; and (4) testing facility management of the GLP facility will ensure that the study director approves the study plan and report.\nWhile we acknowledge the actions that your site has taken and plans to take, your written response is inadequate because you did not provide sufficient details about your corrective action plan. Specifically, you did not provide sufficient details about the procedures and practices for preparing final reports that have been or will be implemented at your site to prevent similar violations in the future. For example, you did not provide details regarding any training for Vedic personnel on your updated procedures and practices. Also, the SOP that you provided does not include all the practices identified in your written response, such as including the name and address of the study director in the final report. Without this information, we cannot undertake an informed evaluation of your written response, and it is not clear whether your corrective and preventive actions will adequately ensure that ongoing and future studies will be conducted in compliance with applicable FDA regulations, including the requirements for preparing final reports.\nFailure to include accurate and complete information in the final study report raises significant concerns about the quality and integrity of the study records and data from Studies (b)(4). The final study report of an investigation is crucial to the reconstruction of the events that led to the collection and reporting of the data, and it must contain accurate and complete information regarding the conduct of the study. The information in these essential documents forms the basis for establishing scientific interpretations and conclusions and must therefore reflect all circumstances affecting the quality and integrity of the data.\nWe further emphasize that nonclinical laboratory studies submitted to FDA must be accurately and completely reported in accordance with FDA regulations, to ensure the quality and integrity of study data. Your failure to provide final reports for all three studies, containing accurate and complete information that is required to be submitted to support FDA’s review of a nonclinical laboratory study, raises significant concerns about the validity and integrity of the data that were collected and submitted for these nonclinical laboratory studies.\nThis letter is not intended to be an all-inclusive list of deficiencies with the nonclinical laboratory studies of investigational drugs for which Vedic was the testing facility, as represented in final reports submitted to FDA. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\nThis letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action without further notice to you. If you believe that you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\nShould you have any questions or concerns about this letter or the inspection, please email FDA at CDER-OSI-Communications@fda.hhs.gov.\nYour written response and any pertinent documentation should be addressed to:\nBrittany L. Garr, MPH\nBranch Chief\nCompliance Enforcement Branch\nDivision of Enforcement and Postmarketing Safety\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\nBuilding 51, Room 5352\n10903 New Hampshire Avenue\nSilver Spring, MD 20993\nSincerely,\n{See appended electronic signature page}\nDavid C. Burrow, Pharm.D., J.D.\nDirector\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n\n--------------------------------------------------------------------------------------------\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n--------------------------------------------------------------------------------------------\n\u002Fs\u002F\n------------------------------------------------------------\nDAVID C BURROW\n03\u002F09\u002F2026 10:48:01 AM","Vedic Lifesciences Pvt. Ltd.","vedic-lifesciences-pvt-ltd-722446-03092026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvedic-lifesciences-pvt-ltd-722446-03092026","2026-10-26T08:10:26.834215+00:00","2026-03-17","722446","Jayesh Chaudhary","2026-08-19T04:51:25.466+00:00","VIA UNITED PARCEL SERVICE AND VIA E-MAIL","26-HFD-45-03-02","2026-03-09",{"id":94,"raw":95,"subject":99,"body_html":101,"body_text":102,"firm_name":60,"letter_id":103,"created_at":18,"fei_number":19,"letter_url":104,"updated_at":105,"action_type":22,"case_status":106,"posted_date":107,"marcs_cms_no":108,"product_type":67,"closeout_date":109,"issuing_office":56,"recipient_name":68,"body_fetched_at":110,"delivery_method":70,"recipient_title":19,"reference_number":111,"action_taken_date":112,"medical_device_id":19,"response_letter_date":19},1269,[96,97,98,56,99,13,100,13],"\u003Ctime datetime=\"2024-09-10T13:20:00Z\">09\u002F10\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-08-29T04:00:00Z\">08\u002F29\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzydus-lifesciences-limited-685224-08292024\">Zydus Lifesciences Limited\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzydus-lifesciences-limited-685224-12092025\">\u003Ctime datetime=\"2025-12-16T05:00:00Z\">12\u002F16\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-24-58\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Sharvil Patel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Zydus Lifesciences Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Zydus Corporate Park, S.G. Highway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nr. Vashnodevi Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ahmedabad\u003C\u002Fspan> \u003Cspan>382482\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-24-58\u003C\u002Fp>\n\n\u003Cp>August 29, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Patel:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Zydus Lifesciences Limited, FEI 3013712903, at Survey No. 434\u002F6\u002FB &amp; 434\u002F1\u002FK, Vadodara – Halol Highway Village - Jarod, Taluka - Waghodia, Gujarat, from April 15 to 23, 2024.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your May 14, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately investigate contamination identified in your drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Cross-contamination\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Over approximately 3 months, you experienced multiple cross-contamination events. Your firm identified cross-contamination from \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product in at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> subsequent other drug product batches manufactured with shared equipment due to inadequate cleaning. Your investigation failed to consider all impacted batches, all manufacturing equipment involved, and the adequacy of your testing methods used to release contaminated drug products.\u003C\u002Fp>\n\n\u003Cp>Notably, your initial cleaning study failed to assess whether your cleaning methods were adequate to clean \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product, which you later found to be “stickier” on product contact surfaces. Your subsequent cleaning studies also did not assess all product contact surfaces. Your firm attempted to implement improved cleaning as a corrective action and preventive action (CAPA) but continued to manufacture and identify cross-contamination.\u003C\u002Fp>\n\n\u003Cp>Furthermore, you released some batches of drug products with results of “not detected” for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination despite identifying contamination that was out of trend (OOT) in other related batches. You provided no rationale for how the samples tested were representative of the potential for overall batch contamination.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you decided to use dedicated equipment for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and committed to monitor batches made on shared equipment through their shelf life for related substances because you continued to observe cross-contamination.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because this type of contamination is generally nonuniformly distributed and testing alone is insufficient to determine the scope of the cross-contamination issue and mitigate associated risks.\u003C\u002Fp>\n\n\u003Cp>On July 2, 2024, you conducted a voluntary recall for Verapamil Hydrochloride Injection, USP 5 mg \u002F 2mL, batches L300255, L300262, L300263; Verapamil Hydrochloride Injection, USP 10 mg\u002F4 mL, batch L300269 for cross-contamination with other products as noted on the following FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002F?Event=94912.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Glass Particulate Contamination\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to adequately investigate and determine the root cause of glass particulate contamination in multiple batches of Cyanocobalamin Injection USP 1000mcg\u002FmL, 1mL found out of limits (OOL) or above alert limits. Without identifying a root cause, you conducted successive visual inspections of batches until glass particulates were within specification and then released batches of Cyanocobalamin Injection USP 1000mcg\u002FmL, 1mL, even though there was potential for glass contamination.\u003C\u002Fp>\n\n\u003Cp>In addition, your operators performing manual visual inspections were not adequately qualified for their ability to identify these defects. For example, your visual inspection qualification kit for Cyanocobalamin Injection USP 1000mcg\u002FmL, 1mL, qualified the operators’ ability to identify glass particles as low as \u003Cstrong>(b)(4)\u003C\u002Fstrong> micrometers in unlabeled \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials. However, the visual inspection of commercial drug product lots of Cyanocobalamin Injection USP 1000mcg\u002FmL, 1mL investigated for glass particle contamination was conducted in labeled \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials that found glass particulates as small as 150 micrometers.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you discontinued the manufacturing of Cyanocobalamin Injection 1000mcg\u002FmL, 1mL in August 2022, and that so far you have not received complaints for glass found in the product. You also state that your visual inspection qualification kits now include appropriately sized particles based on probability of detection and that you will inspect control samples monthly through expiry for particles.\u003C\u002Fp>\n\n\u003Cp>You response is inadequate. The lack of current customer complaints alone is neither a verification of a robust quality system nor indication that you have appropriate process controls in place to conclude that glass fragments may not be present in your products.\u003C\u002Fp>\n\n\u003Cp>On June 27, 2024, you conducted a voluntary recall for Cyanocobalamin Injection USP 1000mcg\u002FmL, 1mL, Batches L200253, L200281, and L200301, for the presence of glass particulate matter as noted on the following FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002F?Event=94914.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit (QU) oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to ensure adequate aseptic behavior and adequate airflow simulations to prevent potential contamination.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Poor Aseptic Behavior\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Our investigators observed multiple instances of poor aseptic techniques during the start-up and filling of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for injection, batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For example, operators disrupted first-air in your ISO-5 areas by reaching over sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials, \u003Cstrong>(b)(4)\u003C\u002Fstrong> stoppers, and the stopper \u003Cstrong>(b)(4)\u003C\u002Fstrong> during interventions without removing the affected vials or stoppers. Additionally, your operators touched \u003Cstrong>(b)(4)\u003C\u002Fstrong> stoppers with the \u003Cstrong>(b)(4)\u003C\u002Fstrong> restricted access barrier system (\u003Cstrong>(b)(4)\u003C\u002Fstrong>-RABS) \u003Cstrong>(b)(4)\u003C\u002Fstrong> while aligning the stopper \u003Cstrong>(b)(4)\u003C\u002Fstrong> during setup.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate Airflow Simulations\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You produced and distributed drug product purporting to be sterile without first conducting adequate process simulations. Specifically, your airflow simulations (smoke studies) for filling line \u003Cstrong>(b)(4)\u003C\u002Fstrong> did not adequately demonstrate unidirectional airflow during \u003Cstrong>(b)(4)\u003C\u002Fstrong> interventions within the \u003Cstrong>(b)(4)\u003C\u002Fstrong>-RABS ISO 5 area. For example, airflow was observed flowing outward and upward during \u003Cstrong>(b)(4)\u003C\u002Fstrong> interventions. However, the simulation did not adequately depict airflow (the smoke was not visible) to determine whether HEPA filtered air was reaching the critical \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Additionally, the design of the stopper conveyer track exiting the stopper \u003Cstrong>(b)(4)\u003C\u002Fstrong> appears to block first-air for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> stoppers moving along the track.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that the lack of visible smoke was due to the location and limited number of smoke sticks during the \u003Cstrong>(b)(4)\u003C\u002Fstrong> condition. You also state that you have conducted new smoke studies. Further, you state that your operators followed procedures, that these “interventions are evaluated during airflow studies,” and that you observed no discrepancies. Lastly, you indicate that there were no media fill or sterility failures for the past 2 years.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because your response does not adequately address the poor aseptic technique that was observed. You also did not address how you will ensure adequate review and approval of qualification and validation studies where deficiencies may exist. In addition, you do not commit to perform a comprehensive review of similar qualification and validation studies to ensure their adequacy.\u003C\u002Fp>\n\n\u003Cp>Any intervention or stoppage during an aseptic process can increase the risk of contamination. The risk to finished product sterility assurance increases with operator interventions in an aseptic processing operation. Your aseptic manufacturing processes should be designed, and operations executed, to prevent contamination hazards to your sterile product. Flaws in the design of cleanrooms and aseptic processing lines, or improper execution of aseptic operations, can promote influx of contamination into the \u003Cstrong>(b)(4)\u003C\u002Fstrong> (ISO 5) processing area.\u003C\u002Fp>\n\n\u003Cp>For additional guidance on aseptic processing see FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\u003Cbr>\n&nbsp; o All human interactions within the ISO 5 area\u003Cbr>\n&nbsp; o Equipment placement and ergonomics\u003Cbr>\n&nbsp; o Air quality in the ISO 5 area and surrounding room\u003Cbr>\n&nbsp; o Facility layout\u003Cbr>\n&nbsp; o Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\u003C\u002Fp>\n\n\u003Cp>• A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\u003C\u002Fp>\n\n\u003Cp>• Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also describe the frequency of QU oversight (e.g., audit) during aseptic processing and its support operations.\u003C\u002Fp>\n\n\u003Cp>• A thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\u003C\u002Fp>\n\n\u003Cp>• An evaluation of the design of the stopper conveyer track to assess the adequacy of unidirectional airflow interacting with your equipment.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100 (a) and 211.100 (b).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your process performance qualifications (PPQ) lack adequate supporting data to assess variability in your manufacturing processes. Specifically, statistical sampling plans were not adequately established and followed to evaluate intra- and inter-batch variation in your PPQs. For example, your PPQ study for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Injection USP \u003Cstrong>(b)(4)\u003C\u002Fstrong>mg\u002Fvial failed to establish acceptance criteria for intra- and inter-batch variation. Instead, \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampling was conducted, reporting singular results for critical quality attributes (CQAs), including assay, impurities, and pH. Sampling and testing between your \u003Cstrong>(b)(4)\u003C\u002Fstrong> used for the PPQ batches also failed to include acceptance criteria for intra- and inter-batch variability for \u003Cstrong>(b)(4)\u003C\u002Fstrong> content.\u003C\u002Fp>\n\n\u003Cp>You also failed to collect \u003Cstrong>(b)(4)\u003C\u002Fstrong> data during your PPQ studies for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products to assess whether stoppering of the vials within your \u003Cstrong>(b)(4)\u003C\u002Fstrong> adequately prevented unintended ingress of air and maintained specified \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that adequate sampling was conducted and that your products are in a state of control, and specifically, that your PPQ intra- and inter-batch variability was observed below \u003Cstrong>(b)(4)\u003C\u002Fstrong>% standard deviation for the CQAs and critical process parameters (CPPs). You commit to revising your procedures to include acceptance criteria for intra- and inter-batch evaluations for variability for your drug products, conduct retrospective reviews, and additional PPQ studies. You also state that you now conduct 100% leak tests for your sterile injectable drug products.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because your evaluation of variability does not appear to be the result of enhanced sampling, but from analytical testing results already provided in your PPQ summary reports which consisted of composite samples and results.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\n\n\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that the FDA considers appropriate elements of process validation, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003Cbr>\n\u003Cbr>\nIn response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\u003C\u002Fp>\n\n\u003Cp>• Timelines for completing further PPQ studies for marketed drug products for which a state of control has not been adequately\u002Ffully established.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Zydus Lifesciences Limited, Survey No. 434\u002F6\u002FB &amp; 434\u002F1\u002FK, Vadodara – Halol Highway Village - Jarod, Taluka - Waghodia, Gujarat into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3013712903 and ATTN: Michael Klapal.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>__________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-24-58\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDr. Sharvil Patel\n\nRecipient Title\n\nManaging Director\n\nZydus Lifesciences Limited\n\nZydus Corporate Park, S.G. Highway\n\nNr. Vashnodevi Circle\n\nAhmedabad 382482\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-24-58\n\nAugust 29, 2024\n\nDear Dr. Patel:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Zydus Lifesciences Limited, FEI 3013712903, at Survey No. 434\u002F6\u002FB & 434\u002F1\u002FK, Vadodara – Halol Highway Village - Jarod, Taluka - Waghodia, Gujarat, from April 15 to 23, 2024.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your May 14, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYou failed to adequately investigate contamination identified in your drug products.\n\nCross-contamination\n\nOver approximately 3 months, you experienced multiple cross-contamination events. Your firm identified cross-contamination from (b)(4) drug product in at least (b)(4) subsequent other drug product batches manufactured with shared equipment due to inadequate cleaning. Your investigation failed to consider all impacted batches, all manufacturing equipment involved, and the adequacy of your testing methods used to release contaminated drug products.\n\nNotably, your initial cleaning study failed to assess whether your cleaning methods were adequate to clean (b)(4) drug product, which you later found to be “stickier” on product contact surfaces. Your subsequent cleaning studies also did not assess all product contact surfaces. Your firm attempted to implement improved cleaning as a corrective action and preventive action (CAPA) but continued to manufacture and identify cross-contamination.\n\nFurthermore, you released some batches of drug products with results of “not detected” for (b)(4) contamination despite identifying contamination that was out of trend (OOT) in other related batches. You provided no rationale for how the samples tested were representative of the potential for overall batch contamination.\n\nIn your response, you state that you decided to use dedicated equipment for (b)(4) and committed to monitor batches made on shared equipment through their shelf life for related substances because you continued to observe cross-contamination.\n\nYour response is inadequate because this type of contamination is generally nonuniformly distributed and testing alone is insufficient to determine the scope of the cross-contamination issue and mitigate associated risks.\n\nOn July 2, 2024, you conducted a voluntary recall for Verapamil Hydrochloride Injection, USP 5 mg \u002F 2mL, batches L300255, L300262, L300263; Verapamil Hydrochloride Injection, USP 10 mg\u002F4 mL, batch L300269 for cross-contamination with other products as noted on the following FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002F?Event=94912.\n\nGlass Particulate Contamination\n\nYour firm failed to adequately investigate and determine the root cause of glass particulate contamination in multiple batches of Cyanocobalamin Injection USP 1000mcg\u002FmL, 1mL found out of limits (OOL) or above alert limits. Without identifying a root cause, you conducted successive visual inspections of batches until glass particulates were within specification and then released batches of Cyanocobalamin Injection USP 1000mcg\u002FmL, 1mL, even though there was potential for glass contamination.\n\nIn addition, your operators performing manual visual inspections were not adequately qualified for their ability to identify these defects. For example, your visual inspection qualification kit for Cyanocobalamin Injection USP 1000mcg\u002FmL, 1mL, qualified the operators’ ability to identify glass particles as low as (b)(4) micrometers in unlabeled (b)(4) vials. However, the visual inspection of commercial drug product lots of Cyanocobalamin Injection USP 1000mcg\u002FmL, 1mL investigated for glass particle contamination was conducted in labeled (b)(4) vials that found glass particulates as small as 150 micrometers.\n\nIn your response, you state that you discontinued the manufacturing of Cyanocobalamin Injection 1000mcg\u002FmL, 1mL in August 2022, and that so far you have not received complaints for glass found in the product. You also state that your visual inspection qualification kits now include appropriately sized particles based on probability of detection and that you will inspect control samples monthly through expiry for particles.\n\nYou response is inadequate. The lack of current customer complaints alone is neither a verification of a robust quality system nor indication that you have appropriate process controls in place to conclude that glass fragments may not be present in your products.\n\nOn June 27, 2024, you conducted a voluntary recall for Cyanocobalamin Injection USP 1000mcg\u002FmL, 1mL, Batches L200253, L200281, and L200301, for the presence of glass particulate matter as noted on the following FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002F?Event=94914.\n\nIn response to this letter, provide a comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit (QU) oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\n2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n\nYou failed to ensure adequate aseptic behavior and adequate airflow simulations to prevent potential contamination.\n\nPoor Aseptic Behavior\n\nOur investigators observed multiple instances of poor aseptic techniques during the start-up and filling of (b)(4) for injection, batch (b)(4). For example, operators disrupted first-air in your ISO-5 areas by reaching over sterile (b)(4) vials, (b)(4) stoppers, and the stopper (b)(4) during interventions without removing the affected vials or stoppers. Additionally, your operators touched (b)(4) stoppers with the (b)(4) restricted access barrier system ((b)(4)-RABS) (b)(4) while aligning the stopper (b)(4) during setup.\n\nInadequate Airflow Simulations\n\nYou produced and distributed drug product purporting to be sterile without first conducting adequate process simulations. Specifically, your airflow simulations (smoke studies) for filling line (b)(4) did not adequately demonstrate unidirectional airflow during (b)(4) interventions within the (b)(4)-RABS ISO 5 area. For example, airflow was observed flowing outward and upward during (b)(4) interventions. However, the simulation did not adequately depict airflow (the smoke was not visible) to determine whether HEPA filtered air was reaching the critical (b)(4).\n\nAdditionally, the design of the stopper conveyer track exiting the stopper (b)(4) appears to block first-air for the (b)(4) stoppers moving along the track.\n\nIn your response, you state that the lack of visible smoke was due to the location and limited number of smoke sticks during the (b)(4) condition. You also state that you have conducted new smoke studies. Further, you state that your operators followed procedures, that these “interventions are evaluated during airflow studies,” and that you observed no discrepancies. Lastly, you indicate that there were no media fill or sterility failures for the past 2 years.\n\nYour response is inadequate because your response does not adequately address the poor aseptic technique that was observed. You also did not address how you will ensure adequate review and approval of qualification and validation studies where deficiencies may exist. In addition, you do not commit to perform a comprehensive review of similar qualification and validation studies to ensure their adequacy.\n\nAny intervention or stoppage during an aseptic process can increase the risk of contamination. The risk to finished product sterility assurance increases with operator interventions in an aseptic processing operation. Your aseptic manufacturing processes should be designed, and operations executed, to prevent contamination hazards to your sterile product. Flaws in the design of cleanrooms and aseptic processing lines, or improper execution of aseptic operations, can promote influx of contamination into the (b)(4) (ISO 5) processing area.\n\nFor additional guidance on aseptic processing see FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\n\nIn response to this letter, provide:\n\n• A comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\n\no All human interactions within the ISO 5 area\n\no Equipment placement and ergonomics\n\no Air quality in the ISO 5 area and surrounding room\n\no Facility layout\n\no Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\n\n• A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\n\n• Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also describe the frequency of QU oversight (e.g., audit) during aseptic processing and its support operations.\n\n• A thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\n\n• An evaluation of the design of the stopper conveyer track to assess the adequacy of unidirectional airflow interacting with your equipment.\n\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100 (a) and 211.100 (b).\n\nYour process performance qualifications (PPQ) lack adequate supporting data to assess variability in your manufacturing processes. Specifically, statistical sampling plans were not adequately established and followed to evaluate intra- and inter-batch variation in your PPQs. For example, your PPQ study for (b)(4) Injection USP (b)(4)mg\u002Fvial failed to establish acceptance criteria for intra- and inter-batch variation. Instead, (b)(4) sampling was conducted, reporting singular results for critical quality attributes (CQAs), including assay, impurities, and pH. Sampling and testing between your (b)(4) used for the PPQ batches also failed to include acceptance criteria for intra- and inter-batch variability for (b)(4) content.\n\nYou also failed to collect (b)(4) data during your PPQ studies for your (b)(4) drug products to assess whether stoppering of the vials within your (b)(4) adequately prevented unintended ingress of air and maintained specified (b)(4).\n\nIn your response, you state that adequate sampling was conducted and that your products are in a state of control, and specifically, that your PPQ intra- and inter-batch variability was observed below (b)(4)% standard deviation for the CQAs and critical process parameters (CPPs). You commit to revising your procedures to include acceptance criteria for intra- and inter-batch evaluations for variability for your drug products, conduct retrospective reviews, and additional PPQ studies. You also state that you now conduct 100% leak tests for your sterile injectable drug products.\n\nYour response is inadequate because your evaluation of variability does not appear to be the result of enhanced sampling, but from analytical testing results already provided in your PPQ summary reports which consisted of composite samples and results.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\n\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that the FDA considers appropriate elements of process validation, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\nIn response to this letter, provide:\n\n• An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\n\n• Timelines for completing further PPQ studies for marketed drug products for which a state of control has not been adequately\u002Ffully established.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Zydus Lifesciences Limited, Survey No. 434\u002F6\u002FB & 434\u002F1\u002FK, Vadodara – Halol Highway Village - Jarod, Taluka - Waghodia, Gujarat into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3013712903 and ATTN: Michael Klapal.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\n__________________\n\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","zydus-lifesciences-limited-685224-08292024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzydus-lifesciences-limited-685224-08292024","2026-10-26T08:10:40.099496+00:00","Closed Out","2024-09-10","685224","2025-12-16","2026-08-19T23:49:53.34+00:00","320-24-58","2024-08-29",{"id":114,"raw":115,"subject":99,"body_html":119,"body_text":120,"firm_name":121,"letter_id":122,"created_at":62,"fei_number":19,"letter_url":123,"updated_at":124,"action_type":22,"case_status":23,"posted_date":125,"marcs_cms_no":126,"product_type":67,"closeout_date":19,"issuing_office":56,"recipient_name":127,"body_fetched_at":128,"delivery_method":29,"recipient_title":19,"reference_number":129,"action_taken_date":130,"medical_device_id":19,"response_letter_date":19},355,[116,117,118,56,99,13,13,13],"\u003Ctime datetime=\"2026-02-03T05:00:00Z\">02\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-01-30T05:00:00Z\">01\u002F30\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcohance-lifesciences-limited-718812-01302026\">Cohance Lifesciences Limited\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-40\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Vetukuri Venkata Naga Kali Vara Prasada Raju\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director &amp; Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Cohance Lifesciences Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>202, 2nd Floor, A-wing, Galaxy by Aurobindo Realty, Sy. No. 83\u002F1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hyderabad Knowledge City, TSIIC, Raidurg, Panmaktha, Opp. IKEA\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hyderabad\u003C\u002Fspan> \u003Cspan>500081\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Telangana\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-40\u003C\u002Fp>\u003Cp>January 30, 2026\u003C\u002Fp>\u003Cp>Dear Dr. Raju:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Cohance Lifesciences Limited, FEI 3008768274, at Plot No. A-19\u002FC, A-23A, A-23B, Road No. 18, IDA Nacharam, Uppal Mandal, Medchal-Malkajgiri, from August 4 to August 12, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your September 2, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures various \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosage forms, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> and medications for the treatment of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your investigations into drug-product quality issues were inadequate because they lacked thoroughness, adequate root-cause determination, and appropriate corrective action and preventive action (CAPA). For example, you received a customer complaint about \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg from two different batches that were reported to be crumbling, disintegrating, pitted, and with dust in the bottle. Your complaint investigation could not identify a root cause and concluded that the complaint was “Not Substantiated.” You noted in your investigation that “the appearance of pitted\u002Fcrumbly tablets is due to the inherent nature of the raw material ‘\u003Cstrong>(b)(4)\u003C\u002Fstrong>’ in the formulation.” Furthermore, your investigation noted two additional complaint investigations for the same issue in three other batches of the same drug product.\u003C\u002Fp>\u003Cp>In your response, you state that you re-opened this investigation and revised your attributable root cause to your raw material, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your response is inadequate. Despite identifying a root cause, your response lacks information on chemical testing of reserve samples to confirm that affected tablets meet specifications, and your response does not contain a commitment to perform such testing. Your response lacks remediation for the root cause identified in your re-opened investigation and does not evaluate the quality of your raw materials or consider changes to your formulation to prevent the issue. Additionally, your response fails to consider whether other drug products containing \u003Cstrong>(b)(4)\u003C\u002Fstrong> could also be affected.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A summary of analytical testing, including dissolution, of reserve samples exhibiting crumbling, disintegrating, pitted \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg, and an action plan to address this product-quality issue, such as reformulation studies or additional transportation studies.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include but not be limited to significant improvements in investigation competencies, scope determination, root-cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root-cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately clean and maintain your nondedicated drug manufacturing equipment. For example, our investigator observed visible stains within the \u003Cstrong>(b)(4)\u003C\u002Fstrong> duct of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> (PD\u002F\u003Cstrong>(b)(4)\u003C\u002Fstrong>-01) and visible residues on a capsule filling machine (PD\u002FCFM-03) that were documented as clean and had undergone drug product changeover cleaning. Your analytical testing of these stains and residues confirmed the presence of multiple active pharmaceutical ingredients (APIs) with values exceeding your allowable limit.\u003C\u002Fp>\u003Cp>In your response, you provide investigations into these findings, including a retrospective review of analytical and stability data for all drug products previously manufactured on the pieces of equipment mentioned above. Your investigations attribute the root cause of the cleaning deficiencies to procedural gaps in the cleaning instructions for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the capsule-filling machine. You state that you plan to revise your cleaning procedures and cleaning checklists.\u003C\u002Fp>\u003Cp>Your response is inadequate because your review of analytical data and cleaning procedures fails to scientifically demonstrate that your drug products are free of contaminants from the visibly dirty equipment. Your response lacks information about reserve sample testing of drug products released to the U.S. market and within expiry, that were manufactured on these pieces of nondedicated equipment, for cross-contamination potential posed by all previously manufactured drug products.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated drug products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one drug product.\u003C\u002Fli>\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all drug products and equipment; and all other needed remediations.\u003C\u002Fli>\u003Cli>In addition to this holistic remediation, provide specific CAPA activities that are being undertaken to effectively remediate the conditions that caused the specific cross-contamination incidents discussed above. Provide an independent review by your consultant that determines the effectiveness of your CAPA, including but not limited to:\u003Cbr>o A list of all enhancements to cleaning and maintenance procedures, including specific frequencies and locations to be cleaned in all relevant equipment (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>)\u003Cbr>o Identification of any sources of cross-contamination other than \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and ductwork\u003Cbr>o Determination of the adequacy of your analytical methodology to identify residual carryover\u003Cbr>o Your investigations into any unknown (unidentified) peaks detected in your reserve samples\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You have not demonstrated that your cleaning practices are adequate to remove contaminants from the shared equipment used to manufacture multiple drug products. Your 2018 cleaning validation study failed to use the identified worst-case drug product, making it inadequate to ensure cleaning effectiveness. You also did not re-evaluate your cleaning validation program when introducing new drug products on shared manufacturing equipment, and you lack routine cleaning verification. Inadequate removal of drug residues during cleaning can cause cross-contamination in subsequently manufactured drugs on the same equipment.\u003C\u002Fp>\u003Cp>In your response, you state that the results of your cleaning verification studies from 2019 to 2024 demonstrate that your cleaning processes are effective. You state that you have engaged an independent third-party consultant to review your cleaning validation program and cleaning practices.\u003C\u002Fp>\u003Cp>Your response is inadequate because your cleaning validation and verification program does not adequately evaluate the effectiveness of your cleaning procedures. Your cleaning verification lacks the ability to detect cross-contamination from carryover.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst-case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003Cbr>o Drugs with higher toxicities\u003Cbr>o Drugs with higher drug potencies\u003Cbr>o Drugs of lower solubility in their cleaning solvents\u003Cbr>o Drugs with characteristics that make them difficult to clean\u003Cbr>o Swabbing locations for areas that are most difficult to clean\u003Cbr>o Maximum hold times before cleaning\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new drug product.\u003C\u002Fp>\u003Cul>\u003Cli>A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for drug products, processes, and equipment.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Drug Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge your commitment to temporarily suspend manufacturing and release of drug products from this facility as of August 16, 2025. In response to this letter, clarify when you intend to resume manufacturing of drugs for the U.S. market at this facility.\u003C\u002Fp>\u003Cp>Before you resume any manufacturing operations regulated under the FD&amp;C Act, notify this office. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Cohance Lifesciences Limited, FEI 3008768274, at Plot No. A-19\u002FC, A-23A, A-23B, Road No. 18, IDA Nacharam, Uppal Mandal, Medchal-Malkajgiri, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3008768274 and ATTN: Marisa Heayn.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-26-40\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDr. Vetukuri Venkata Naga Kali Vara Prasada Raju\n\nRecipient Title\n\nManaging Director & Chief Executive Officer\n\nCohance Lifesciences Limited\n\n202, 2nd Floor, A-wing, Galaxy by Aurobindo Realty, Sy. No. 83\u002F1\n\nHyderabad Knowledge City, TSIIC, Raidurg, Panmaktha, Opp. IKEA\n\nHyderabad 500081\n\nTelangana\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-40\nJanuary 30, 2026\nDear Dr. Raju:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Cohance Lifesciences Limited, FEI 3008768274, at Plot No. A-19\u002FC, A-23A, A-23B, Road No. 18, IDA Nacharam, Uppal Mandal, Medchal-Malkajgiri, from August 4 to August 12, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your September 2, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following:\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYour firm manufactures various (b)(4) dosage forms, including (b)(4) and medications for the treatment of (b)(4). Your investigations into drug-product quality issues were inadequate because they lacked thoroughness, adequate root-cause determination, and appropriate corrective action and preventive action (CAPA). For example, you received a customer complaint about (b)(4) tablets USP (b)(4) mg from two different batches that were reported to be crumbling, disintegrating, pitted, and with dust in the bottle. Your complaint investigation could not identify a root cause and concluded that the complaint was “Not Substantiated.” You noted in your investigation that “the appearance of pitted\u002Fcrumbly tablets is due to the inherent nature of the raw material ‘(b)(4)’ in the formulation.” Furthermore, your investigation noted two additional complaint investigations for the same issue in three other batches of the same drug product.\nIn your response, you state that you re-opened this investigation and revised your attributable root cause to your raw material, (b)(4).\nYour response is inadequate. Despite identifying a root cause, your response lacks information on chemical testing of reserve samples to confirm that affected tablets meet specifications, and your response does not contain a commitment to perform such testing. Your response lacks remediation for the root cause identified in your re-opened investigation and does not evaluate the quality of your raw materials or consider changes to your formulation to prevent the issue. Additionally, your response fails to consider whether other drug products containing (b)(4) could also be affected.\nIn response to this letter, provide:\nA summary of analytical testing, including dissolution, of reserve samples exhibiting crumbling, disintegrating, pitted (b)(4) tablets USP (b)(4) mg, and an action plan to address this product-quality issue, such as reformulation studies or additional transportation studies.\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include but not be limited to significant improvements in investigation competencies, scope determination, root-cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nAn independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root-cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\n2. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\nYou failed to adequately clean and maintain your nondedicated drug manufacturing equipment. For example, our investigator observed visible stains within the (b)(4) duct of a (b)(4) (PD\u002F(b)(4)-01) and visible residues on a capsule filling machine (PD\u002FCFM-03) that were documented as clean and had undergone drug product changeover cleaning. Your analytical testing of these stains and residues confirmed the presence of multiple active pharmaceutical ingredients (APIs) with values exceeding your allowable limit.\nIn your response, you provide investigations into these findings, including a retrospective review of analytical and stability data for all drug products previously manufactured on the pieces of equipment mentioned above. Your investigations attribute the root cause of the cleaning deficiencies to procedural gaps in the cleaning instructions for the (b)(4) and the capsule-filling machine. You state that you plan to revise your cleaning procedures and cleaning checklists.\nYour response is inadequate because your review of analytical data and cleaning procedures fails to scientifically demonstrate that your drug products are free of contaminants from the visibly dirty equipment. Your response lacks information about reserve sample testing of drug products released to the U.S. market and within expiry, that were manufactured on these pieces of nondedicated equipment, for cross-contamination potential posed by all previously manufactured drug products.\nIn response to this letter, provide:\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated drug products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one drug product.\nA CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all drug products and equipment; and all other needed remediations.\nIn addition to this holistic remediation, provide specific CAPA activities that are being undertaken to effectively remediate the conditions that caused the specific cross-contamination incidents discussed above. Provide an independent review by your consultant that determines the effectiveness of your CAPA, including but not limited to:\no A list of all enhancements to cleaning and maintenance procedures, including specific frequencies and locations to be cleaned in all relevant equipment (e.g., (b)(4))\no Identification of any sources of cross-contamination other than (b)(4) equipment, (b)(4), and ductwork\no Determination of the adequacy of your analytical methodology to identify residual carryover\no Your investigations into any unknown (unidentified) peaks detected in your reserve samples\n3. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\nYou have not demonstrated that your cleaning practices are adequate to remove contaminants from the shared equipment used to manufacture multiple drug products. Your 2018 cleaning validation study failed to use the identified worst-case drug product, making it inadequate to ensure cleaning effectiveness. You also did not re-evaluate your cleaning validation program when introducing new drug products on shared manufacturing equipment, and you lack routine cleaning verification. Inadequate removal of drug residues during cleaning can cause cross-contamination in subsequently manufactured drugs on the same equipment.\nIn your response, you state that the results of your cleaning verification studies from 2019 to 2024 demonstrate that your cleaning processes are effective. You state that you have engaged an independent third-party consultant to review your cleaning validation program and cleaning practices.\nYour response is inadequate because your cleaning validation and verification program does not adequately evaluate the effectiveness of your cleaning procedures. Your cleaning verification lacks the ability to detect cross-contamination from carryover.\nIn response to this letter, provide:\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst-case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\no Drugs with higher toxicities\no Drugs with higher drug potencies\no Drugs of lower solubility in their cleaning solvents\no Drugs with characteristics that make them difficult to clean\no Swabbing locations for areas that are most difficult to clean\no Maximum hold times before cleaning\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new drug product.\nA summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for drug products, processes, and equipment.\nDrug Production Suspended\nWe acknowledge your commitment to temporarily suspend manufacturing and release of drug products from this facility as of August 16, 2025. In response to this letter, clarify when you intend to resume manufacturing of drugs for the U.S. market at this facility.\nBefore you resume any manufacturing operations regulated under the FD&C Act, notify this office. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Cohance Lifesciences Limited, FEI 3008768274, at Plot No. A-19\u002FC, A-23A, A-23B, Road No. 18, IDA Nacharam, Uppal Mandal, Medchal-Malkajgiri, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.1 Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3008768274 and ATTN: Marisa Heayn.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n______________________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Cohance Lifesciences Limited","cohance-lifesciences-limited-718812-01302026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcohance-lifesciences-limited-718812-01302026","2026-10-26T08:08:16.746596+00:00","2026-02-03","718812","Dr. Vetukuri Venkata Naga Kali Vara Prasada Raju","2026-08-19T05:07:44.869+00:00","320-26-40","2026-01-30",{"id":132,"raw":133,"subject":99,"body_html":138,"body_text":139,"firm_name":140,"letter_id":141,"created_at":41,"fei_number":19,"letter_url":142,"updated_at":143,"action_type":22,"case_status":23,"posted_date":144,"marcs_cms_no":145,"product_type":67,"closeout_date":19,"issuing_office":137,"recipient_name":146,"body_fetched_at":147,"delivery_method":70,"recipient_title":19,"reference_number":19,"action_taken_date":148,"medical_device_id":19,"response_letter_date":19},1954,[134,135,136,137,99,13,13,13],"\u003Ctime datetime=\"2023-08-08T13:20:00Z\">08\u002F08\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-03T04:00:00Z\">08\u002F03\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Forchid-lifesciences-663478-08032023\">Orchid Lifesciences\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Smit Patel Managing\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Director and Marketing Head\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Orchid Lifesciences\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>68-72 Tribhuvan Industrial Estate\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nr. Road No. 11, Kathwada\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ahmedabad, Kathwada\u003C\u002Fspan> \u003Cspan>382430\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:smit@orchidlifesciences.com\"> smit@orchidlifesciences.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-23-23\u003C\u002Fp>\n\n\u003Cp>August 3, 2023\u003Cbr>\n\u003Cbr>\nDear Mr. Smit Patel:\u003C\u002Fp>\n\n\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our January 25, 2023 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Orchid Lifesciences, FEI 3015154915, 68-72 Tribhuvan Industrial Estate, Nr. Road No. 11, Kathwada, Ahmedabad, Kathwada, India 382430.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\n\n\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You manufacture several over-the-counter (OTC) drug products including toothpaste and topical analgesics. Based on the records and information you provided, you did not demonstrate that you adequately tested each shipment of each lot of the incoming components at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination. These include, but are not limited to, testing of glycerin, propylene glycol, and sorbitol solution, you used in manufacturing drug products to determine their appropriate identity. Identity testing for these and certain other high-risk drug components\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> include a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination. Take prompt and appropriate actions to determine the safety of all lots of the components and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high- risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\n\t\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not adequately exercise its authority in the approval or rejection of components in your Materials System.\u003C\u002Fp>\n\n\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may also not be conducting appropriate oversight regarding other CGMP operations, including Production, Facilities &amp; Equipment, Laboratory Controls, and Packaging &amp; Labelling Systems.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on March 23, 2023.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 30 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3015154915 and ATTN: Matthew R. Dionne, Pharm.D., Compliance Officer.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>CC (via email):\u003Cbr>\nLiberty Management Group Ltd.\u003Cbr>\nManoj@libertymanagement.us\u003C\u002Fp>\n\n\u003Cp>____________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Components with higher risk of DEG or EG contamination compared to other drug components.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nSmit Patel Managing\n\nRecipient Title\n\nDirector and Marketing Head\n\nOrchid Lifesciences\n\n68-72 Tribhuvan Industrial Estate\n\nNr. Road No. 11, Kathwada\n\nAhmedabad, Kathwada 382430\n\nIndia\n\nsmit@orchidlifesciences.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-23-23\n\nAugust 3, 2023\n\nDear Mr. Smit Patel:\n\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our January 25, 2023 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Orchid Lifesciences, FEI 3015154915, 68-72 Tribhuvan Industrial Estate, Nr. Road No. 11, Kathwada, Ahmedabad, Kathwada, India 382430.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)).\n\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\n\nYou manufacture several over-the-counter (OTC) drug products including toothpaste and topical analgesics. Based on the records and information you provided, you did not demonstrate that you adequately tested each shipment of each lot of the incoming components at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination. These include, but are not limited to, testing of glycerin, propylene glycol, and sorbitol solution, you used in manufacturing drug products to determine their appropriate identity. Identity testing for these and certain other high-risk drug components1 include a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug products.\n\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nIn response to this letter, provide:\n\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\n\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination. Take prompt and appropriate actions to determine the safety of all lots of the components and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high- risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\n\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\n2. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\n\nThe records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not adequately exercise its authority in the approval or rejection of components in your Materials System.\n\nYour QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may also not be conducting appropriate oversight regarding other CGMP operations, including Production, Facilities & Equipment, Laboratory Controls, and Packaging & Labelling Systems.\n\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit2 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on March 23, 2023.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 30 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3015154915 and ATTN: Matthew R. Dionne, Pharm.D., Compliance Officer.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC (via email):\n\nLiberty Management Group Ltd.\n\nManoj@libertymanagement.us\n\n____________________________\n\n1 Components with higher risk of DEG or EG contamination compared to other drug components.\n\n2 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Orchid Lifesciences","orchid-lifesciences-663478-08032023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Forchid-lifesciences-663478-08032023","2026-10-26T08:09:38.852527+00:00","2023-08-08","663478","Smit Patel Managing","2026-08-20T00:48:54.41+00:00","2023-08-03",{"id":150,"raw":151,"subject":99,"body_html":155,"body_text":156,"firm_name":157,"letter_id":158,"created_at":18,"fei_number":19,"letter_url":159,"updated_at":160,"action_type":22,"case_status":23,"posted_date":161,"marcs_cms_no":162,"product_type":67,"closeout_date":19,"issuing_office":56,"recipient_name":163,"body_fetched_at":164,"delivery_method":165,"recipient_title":19,"reference_number":166,"action_taken_date":167,"medical_device_id":19,"response_letter_date":19},1167,[152,153,154,56,99,13,13,13],"\u003Ctime datetime=\"2024-11-19T14:20:00Z\">11\u002F19\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-11-06T05:00:00Z\">11\u002F06\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funexo-lifesciences-private-limited-688163-11062024\">Unexo Lifesciences, Private Limited\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-11\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Saurabh Bansal\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Unexo Lifesciences, Private Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>B16 Sector 4\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bawana Industrial Area\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>New Delhi\u003C\u002Fspan> \u003Cspan>110039\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Delhi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-11\u003C\u002Fp>\n\n\u003Cp>November 6, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Bansal:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Unexo Life Sciences, Private Limited, FEI 3013514280, located at B16, Sector 4, Bawana Industrial Area, New Delhi, Delhi, 110039 India, from May 1 to 14, 2024.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your June 04, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to provide adequate oversight and ensure the reliability of data related to the quality of finished drug products manufactured at your facility. Your quality assurance (QA) department was not exercising its basic responsibilities for the oversight and control over the adequacy and reliability of all CGMP data at your facility. In addition, your QA department is responsible for ensuring your employees understand and adhere to data integrity principles.\u003C\u002Fp>\n\n\u003Cp>A. You failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188). For example, batch production records were found torn in plastic bags on your rooftop. Among the torn records were missing batch production records that you were not able to locate during the inspection for your drug product, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Patch, batches \u003Cstrong>(b)(4)\u003C\u002Fstrong> which were intended for the U.S. market. The torn records also included duplicate incomplete batch production records with the same batch numbers and issuance dates as the batch records already provided to the investigators, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> Patch batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Patch batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> also intended for the U.S. market.\u003C\u002Fp>\n\n\u003Cp>Your executive management admitted to not having all the batch records for the released drug products and batch production records were “retrospectively prepared” to provide to the investigators.\u003C\u002Fp>\n\n\u003Cp>In your response, you commit to investigate the retrospectively created batch records and perform assessments regarding your data integrity practices and capabilities of your quality unit (QU) organization to meet CGMP compliance and “sustain a quality culture”. In addition, you indicate you reconciled batch records for all batches manufactured (\u003Cstrong>(b)(4)\u003C\u002Fstrong> batches) for the U.S. market within expiry, and these records are under review by a qualified independent consultant. You state batches \u003Cstrong>(b)(4)\u003C\u002Fstrong> will be rejected and destroyed.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You do not share in detail how you will detect and investigate for non-contemporaneously prepared records. Considering you created records during the inspection, FDA is concerned regarding the validity of your reconciled records generated at your facility for all products within expiry. Additionally, you do not provide a rationale for only rejecting and destroying select batches, and you do not include adequate assurance the batches in U.S. distribution are consistently manufactured to ensure the products are safe and effective.\u003C\u002Fp>\n\n\u003Cp>Complete and accurate batch production and control records must be contemporaneously documented to ensure that manufacturing processes are consistently followed and reproducible. Additionally, incomplete manufacturing records deprive you of the ability to adequately investigate deviations.\u003C\u002Fp>\n\n\u003Cp>B. You failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21CFR211.194(a)). You lacked raw data to support the product testing for released drug products. For example, your internal test report for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Patch product, batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was missing the individual results for assay, patch weight, peel strength analysis and rolling ball analysis. Your quality management acknowledged you did not have the data for the peel strength and rolling ball analyses for batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and provided no explanation when asked how you released the batch without the data.\u003C\u002Fp>\n\n\u003Cp>In your response you state that you initiated a deviation to investigate instances where the raw data is not available, and have a third-party consultant perform a comprehensive assessment on data integrity practices at your site. Also, as part of your current controls, you explain the analyst checks the raw data and results against the specification for compliance, while the laboratory manager verifies preparations, analyzed results, and approves the individual test.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You do not provide a copy of your initiated deviation with a detailed investigation plan for identifying incomplete laboratory records. You do not provide sufficient details describing how data integrity deficiencies will be detected and documented by your third-party consultant. Additionally, it is unclear whether your raw data review process has adequate oversight by your QA to ensure ALCOA (attributable, legible, contemporaneously recorded, original or a true copy, and accurate) principles are followed throughout your laboratory operations.\u003C\u002Fp>\n\n\u003Cp>Reliability of data is fundamentally compromised when there is a failure to record or maintain complete and accurate records of test results, or conditions associated with all tests. Furthermore, the lack of reliable data compromises the QA’s ability to exercise its function of ensuring compliance to applicable standards.\u003C\u002Fp>\n\n\u003Cp>C. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)). For example, your QC analyst had the ability to manipulate results, dates, and images of in-house and vendor stamp approvals on component certificate of analyses (COAs) from third-party contract laboratories, including the means to duplicate the stamp approval across multiple COAs for components, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>In your response, you explain the analyst involved with access to unauthorized test data was removed from regular duties, however, your response is inadequate because it does not explain in detail how appropriate controls will be implemented for maintaining data integrity and defining user privileges for computer systems, including measures for appropriate oversight and maintenance of data and results from third-party contract laboratories.\u003C\u002Fp>\n\n\u003Cp>Customers rely on the integrity of the laboratory records you create, approve, and manage. It is important to maintain strict control over CGMP electronic data to ensure that all additions, deletions, or modifications of information in your electronic records are authorized and appropriately documented.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP\u003C\u002Fem> compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>We acknowledge that you are using an independent third-party consultant to audit your operation and assist in meeting FDA requirements.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\u003Cbr>\n&nbsp; &nbsp; o Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003Cbr>\n&nbsp; &nbsp; o An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\u003Cbr>\n&nbsp; &nbsp; o A comprehensive retrospective assessment of all raw data and results in which your QC analyst(s) had the ability to manipulate results, dates, and images of in-house and vendor stamp approvals for data integrity inaccuracies and deficiencies.\u003Cbr>\n&nbsp; &nbsp; o A comprehensive retrospective evaluation of the nature of the data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\n\t\u003Cli>A management strategy for your firm that includes the details of your global corrective action and preventive action (CAPA) plan. Your strategy should include:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\u003Cbr>\n&nbsp; &nbsp; o A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\u003Cbr>\n&nbsp; &nbsp; o Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\u003Cbr>\n&nbsp; &nbsp; o Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\u003Cbr>\n&nbsp; &nbsp; o A commitment to have a qualified consultant conduct extensive annual audits, for at least 2 years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\u003Cbr>\n&nbsp; &nbsp; o Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent QA function, along with expertise from outside entities whenever needed).\u003Cbr>\n&nbsp; &nbsp; o A status report for any of the above activities already underway or completed.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production and laboratory operations, we found your QU is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our investigators observed unclean air conditioner vents above production areas that include the \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine in which \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products are exposed to the air flowing from the unclean vents.\u003C\u002Fp>\n\n\u003Cp>In your response, you state the air conditioners are used to cool and recirculate the air from the air-handling unit, and you commit to investigate the cleaning deficiency for all your air conditioners in the facility.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because it does not include a copy of the investigation and corrective actions indicated. Also, your response is unclear because it does not specify if you intend to identify the residue on the unclean air conditioner vents and evaluate your cleaning procedures. Additionally, you do not provide an assessment of previously manufactured drug products or testing of reserve samples from impacted batches.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A copy of your initiated deviation, UDF\u002FPRD\u002F2024\u002F024.\u003C\u002Fli>\n\t\u003Cli>A copy of your cleaning procedure and most recent cleaning verification studies of the air conditioners at your facility.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\n\t\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\n\t\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Drugs with higher toxicities\u003Cbr>\n&nbsp; &nbsp; o Drugs with higher drug potencies\u003Cbr>\n&nbsp; &nbsp; o Drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; &nbsp; o Drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Maximum hold times before cleaning\u003C\u002Fp>\n\n\u003Cp>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A summary of updated standard operating procedures that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\n\t\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Access to Information During Inspection\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During the inspection, the only computer alleged to have all the electronic CGMP data, which was not backed up, was not available because the QC analyst took the computer home and could not be reached after multiple attempts. Additionally the QC manager’s computer was requested to review COAs and test procedures, however, when the laptop was provided all recent files and drives were apparently deleted before being presented to the investigators. This limited FDA’s access to records for inspection to evaluate the CGMP compliance status of your facility.\u003C\u002Fp>\n\n\u003Cp>Additionally, you reported your QC analyst was receiving COAs from your third-party contract laboratory in Word format via WhatsApp on his personal cell phone, and he confirmed to have deleted all the received COAs. You do not have appropriate controls to assure integrity and traceability of your COAs from your third-party contract laboratories.\u003C\u002Fp>\n\n\u003Cp>When an owner, operator, or agent delays, denies, limits, or refuses an inspection, the drugs may be deemed adulterated under section 501(j) of the FD&amp;C Act. See FDA’s guidance document \u003Cem>Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86328\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Production Suspended and Drug Recall\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your decision to temporarily cease the manufacturing of products made at your facility intended for U.S. distribution.\u003C\u002Fp>\n\n\u003Cp>On October 8, 2024, FDA held a teleconference with you recommending you initiate a voluntary recall of all batches of drug product manufactured from your facility in distribution and intended for the U.S. market that remain within expiry.\u003C\u002Fp>\n\n\u003Cp>On October 9, 2024, you committed to a voluntary recall of certain drugs due to the significant CGMP violations. Provide an update on your efforts to initiate the recall.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, clarify whether you intend to resume manufacturing drugs for the U.S. market at this facility in the future.\u003C\u002Fp>\n\n\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective actions and preventive actions (CAPAs).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Unexo Life Sciences, Private Limited, located at B16, Sector 4, Bawana Industrial Area, New Delhi, Delhi 110039, India into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3013514280 and ATTN: Sai Dharmaraj.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-25-11\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Saurabh Bansal\n\nRecipient Title\n\nManaging Director\n\nUnexo Lifesciences, Private Limited\n\nB16 Sector 4\n\nBawana Industrial Area\n\nNew Delhi 110039\n\nDelhi\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-11\n\nNovember 6, 2024\n\nDear Mr. Bansal:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Unexo Life Sciences, Private Limited, FEI 3013514280, located at B16, Sector 4, Bawana Industrial Area, New Delhi, Delhi, 110039 India, from May 1 to 14, 2024.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your June 04, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\n1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour firm failed to provide adequate oversight and ensure the reliability of data related to the quality of finished drug products manufactured at your facility. Your quality assurance (QA) department was not exercising its basic responsibilities for the oversight and control over the adequacy and reliability of all CGMP data at your facility. In addition, your QA department is responsible for ensuring your employees understand and adhere to data integrity principles.\n\nA. You failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188). For example, batch production records were found torn in plastic bags on your rooftop. Among the torn records were missing batch production records that you were not able to locate during the inspection for your drug product, (b)(4) Patch, batches (b)(4) which were intended for the U.S. market. The torn records also included duplicate incomplete batch production records with the same batch numbers and issuance dates as the batch records already provided to the investigators, such as (b)(4) Patch batch (b)(4) and (b)(4) Patch batch (b)(4) also intended for the U.S. market.\n\nYour executive management admitted to not having all the batch records for the released drug products and batch production records were “retrospectively prepared” to provide to the investigators.\n\nIn your response, you commit to investigate the retrospectively created batch records and perform assessments regarding your data integrity practices and capabilities of your quality unit (QU) organization to meet CGMP compliance and “sustain a quality culture”. In addition, you indicate you reconciled batch records for all batches manufactured ((b)(4) batches) for the U.S. market within expiry, and these records are under review by a qualified independent consultant. You state batches (b)(4) will be rejected and destroyed.\n\nYour response is inadequate. You do not share in detail how you will detect and investigate for non-contemporaneously prepared records. Considering you created records during the inspection, FDA is concerned regarding the validity of your reconciled records generated at your facility for all products within expiry. Additionally, you do not provide a rationale for only rejecting and destroying select batches, and you do not include adequate assurance the batches in U.S. distribution are consistently manufactured to ensure the products are safe and effective.\n\nComplete and accurate batch production and control records must be contemporaneously documented to ensure that manufacturing processes are consistently followed and reproducible. Additionally, incomplete manufacturing records deprive you of the ability to adequately investigate deviations.\n\nB. You failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21CFR211.194(a)). You lacked raw data to support the product testing for released drug products. For example, your internal test report for (b)(4) Patch product, batch (b)(4), was missing the individual results for assay, patch weight, peel strength analysis and rolling ball analysis. Your quality management acknowledged you did not have the data for the peel strength and rolling ball analyses for batch (b)(4), and provided no explanation when asked how you released the batch without the data.\n\nIn your response you state that you initiated a deviation to investigate instances where the raw data is not available, and have a third-party consultant perform a comprehensive assessment on data integrity practices at your site. Also, as part of your current controls, you explain the analyst checks the raw data and results against the specification for compliance, while the laboratory manager verifies preparations, analyzed results, and approves the individual test.\n\nYour response is inadequate. You do not provide a copy of your initiated deviation with a detailed investigation plan for identifying incomplete laboratory records. You do not provide sufficient details describing how data integrity deficiencies will be detected and documented by your third-party consultant. Additionally, it is unclear whether your raw data review process has adequate oversight by your QA to ensure ALCOA (attributable, legible, contemporaneously recorded, original or a true copy, and accurate) principles are followed throughout your laboratory operations.\n\nReliability of data is fundamentally compromised when there is a failure to record or maintain complete and accurate records of test results, or conditions associated with all tests. Furthermore, the lack of reliable data compromises the QA’s ability to exercise its function of ensuring compliance to applicable standards.\n\nC. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)). For example, your QC analyst had the ability to manipulate results, dates, and images of in-house and vendor stamp approvals on component certificate of analyses (COAs) from third-party contract laboratories, including the means to duplicate the stamp approval across multiple COAs for components, such as (b)(4), lot (b)(4), lot (b)(4).\n\nIn your response, you explain the analyst involved with access to unauthorized test data was removed from regular duties, however, your response is inadequate because it does not explain in detail how appropriate controls will be implemented for maintaining data integrity and defining user privileges for computer systems, including measures for appropriate oversight and maintenance of data and results from third-party contract laboratories.\n\nCustomers rely on the integrity of the laboratory records you create, approve, and manage. It is important to maintain strict control over CGMP electronic data to ensure that all additions, deletions, or modifications of information in your electronic records are authorized and appropriately documented.\n\nData Integrity Remediation\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\n\nWe acknowledge that you are using an independent third-party consultant to audit your operation and assist in meeting FDA requirements.\n\nIn response to this letter, provide:\n\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\n\no A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\n\no Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\n\no An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\n\no A comprehensive retrospective assessment of all raw data and results in which your QC analyst(s) had the ability to manipulate results, dates, and images of in-house and vendor stamp approvals for data integrity inaccuracies and deficiencies.\n\no A comprehensive retrospective evaluation of the nature of the data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\n\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\nA management strategy for your firm that includes the details of your global corrective action and preventive action (CAPA) plan. Your strategy should include:\n\no A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\n\no A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\n\no Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\n\no Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\n\no A commitment to have a qualified consultant conduct extensive annual audits, for at least 2 years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\n\no Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent QA function, along with expertise from outside entities whenever needed).\n\no A status report for any of the above activities already underway or completed.\n\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\nIneffective Quality System\n\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production and laboratory operations, we found your QU is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\n\n2. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\n\nOur investigators observed unclean air conditioner vents above production areas that include the (b)(4) machine in which (b)(4) drug products are exposed to the air flowing from the unclean vents.\n\nIn your response, you state the air conditioners are used to cool and recirculate the air from the air-handling unit, and you commit to investigate the cleaning deficiency for all your air conditioners in the facility.\n\nYour response is inadequate because it does not include a copy of the investigation and corrective actions indicated. Also, your response is unclear because it does not specify if you intend to identify the residue on the unclean air conditioner vents and evaluate your cleaning procedures. Additionally, you do not provide an assessment of previously manufactured drug products or testing of reserve samples from impacted batches.\n\nIn response to this letter, provide:\n\nA copy of your initiated deviation, UDF\u002FPRD\u002F2024\u002F024.\n\nA copy of your cleaning procedure and most recent cleaning verification studies of the air conditioners at your facility.\n\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\n\nA CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\n\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\n\no Drugs with higher toxicities\n\no Drugs with higher drug potencies\n\no Drugs of lower solubility in their cleaning solvents\n\no Drugs with characteristics that make them difficult to clean\n\no Swabbing locations for areas that are most difficult to clean\n\no Maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\n\nA summary of updated standard operating procedures that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n\nAccess to Information During Inspection\n\nDuring the inspection, the only computer alleged to have all the electronic CGMP data, which was not backed up, was not available because the QC analyst took the computer home and could not be reached after multiple attempts. Additionally the QC manager’s computer was requested to review COAs and test procedures, however, when the laptop was provided all recent files and drives were apparently deleted before being presented to the investigators. This limited FDA’s access to records for inspection to evaluate the CGMP compliance status of your facility.\n\nAdditionally, you reported your QC analyst was receiving COAs from your third-party contract laboratory in Word format via WhatsApp on his personal cell phone, and he confirmed to have deleted all the received COAs. You do not have appropriate controls to assure integrity and traceability of your COAs from your third-party contract laboratories.\n\nWhen an owner, operator, or agent delays, denies, limits, or refuses an inspection, the drugs may be deemed adulterated under section 501(j) of the FD&C Act. See FDA’s guidance document Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86328\u002Fdownload.\n\nProduction Suspended and Drug Recall\n\nWe acknowledge your decision to temporarily cease the manufacturing of products made at your facility intended for U.S. distribution.\n\nOn October 8, 2024, FDA held a teleconference with you recommending you initiate a voluntary recall of all batches of drug product manufactured from your facility in distribution and intended for the U.S. market that remain within expiry.\n\nOn October 9, 2024, you committed to a voluntary recall of certain drugs due to the significant CGMP violations. Provide an update on your efforts to initiate the recall.\n\nIn response to this letter, clarify whether you intend to resume manufacturing drugs for the U.S. market at this facility in the future.\n\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective actions and preventive actions (CAPAs).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\n(b)(4)\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Unexo Life Sciences, Private Limited, located at B16, Sector 4, Bawana Industrial Area, New Delhi, Delhi 110039, India into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3013514280 and ATTN: Sai Dharmaraj.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research","Unexo Lifesciences, Private Limited","unexo-lifesciences-private-limited-688163-11062024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funexo-lifesciences-private-limited-688163-11062024","2026-10-26T08:10:17.43834+00:00","2024-11-19","688163","Mr. Saurabh Bansal","2026-08-19T18:45:40.523+00:00","Via Email","320-25-11","2024-11-06",8,{"510k":170,"classification":171,"enforcement":172,"event":173,"event_backfill":174,"pma":175,"warning_letter":176},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]